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Success is not final, failure is not fatal: it is the courage to continue that counts. 
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Sumário 
 
As hepatites virais e a doença hepática gorda não alcoólica são actualmente as causas 
mais frequentes de doença hepática crónica. Qualquer uma destas patologias é 
caracterizada pela presença no parênquima hepático de esteatose, inflamação e fibrose, 
que podem agravar-se e levar a uma situação clínica de insuficiência hepática, causando 
não só considerável morbilidade mas também mortalidade, e igualmente um real 
incremento nos custos nacionais com a saúde. A capacidade de deteção precoce, por 
rotina, de estádios ligeiros/moderados de inflamação e fibrose e a quantificação da 
esteatose através de meios de imagem não invasivos, poderá trazer vantagens clínicas 
importantes para estes doentes e para a sociedade.  
No presente estudo aqui desenvolvido, a fibrose, inflamação e  a esteatose hepáticas 
foram avaliadas de forma não invasiva por ressonância magnética, com sequências de 
eco de gradiente e sequências ponderadas em difusão, elastografia por ressonância 
magnética e imagem molecular em ressonância magnética. Foi igualmente utilizada a 
ecografia com elastografia supersónica por onda de cisalhamento. Do conjunto de 
estudos aqui apresentados foi possível observar: 
- A esteatose hepática pode ser quantificada de forma precisa e simples, utilizando 
um mapeamento total da gordura hepática por ressonância magnética. Assim, 
será possível diagnosticar precocemente os doentes com fígado gordo não 
alcoólico; 
- Os parâmetros viscoelásticos são mais precisos que os parâmetros de difusão no 
estadiamento da fibrose hepática. Determinar precocemente quais os doentes 
com estádios de fibrose F2 é fundamental para o início da terapêutica antiviral; 
- Os parâmetros viscoelásticos independentes da frequência de excitação são 
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potenciais biomarcadores de inflamação hepática. Até hoje ainda não existia 
nenhum biomarcador por imagem focado apenas para a inflamação hepática, 
mas a deteção precisa desta evitaria, por exemplo, que os doentes com fígado 
gordo não alcoólico progredissem para um quadro de esteatohepatite não 
alcoólica e uma melhor avaliação do parênquima hepático nos doentes com 
hepatites virais;  
- A ecografia com elastografia supersónica por onda de cisalhamento é proposta 
como uma técnica adequada para o rastreio de doentes com fibrose hepática; 
- Finalmente, uma abordagem experimental em imagem molecular utilizando um 
contraste de ressonância magnética vectorizado especificamente para a fibrina, 
permitiu a deteção de fibrose no prênquima hepático em ratos injectados com 
dietilnitrosamina. 
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Summary 
 
Viral hepatitis and nonalcoholic fatty liver disease are nowadays the most common 
causes of chronic liver disease. These disorders, which are characterized by 
parenchymal steatosis, inflammation and fibrosis can progress to liver failure and are a 
substantial source of morbidity, mortality and increased healthcare costs. The early 
detection of fibrosis and inflammation and the routinely quantification of steatosis by 
noninvasive methods have important clinical implications in these patients. 
In the current study liver fibrosis, inflammation and steatosis, were noninvasively 
assessed by magnetic resonance gradient echo imaging, intravoxel incoherent motion 
diffusion-weighted imaging, magnetic resonance elastography, ultrasound-based shear 
wave elastography and molecular imaging. Liver fat content was accurately quantified 
by a simple and fast mapping technique using magnetic resonance imaging, which can 
allow the early detection of patients with nonalcoholic fatty liver. In addition, magnetic 
resonance viscoelastic parameters were found to be more accurate than diffusion 
parameters to stage patients with liver fibrosis. Determining when a patient reaches an 
F2 fibrosis stage is crucial to start antiviral treatment. Moreover, a frequency-
independent viscoelastic parameter is proposed as a potential biomarker for liver 
inflammation. The early detection of increased liver inflammation can prevent patients 
with nonalcoholic fatty liver from progressing to nonalcoholic steatohepatitis and 
enables an adequate follow up of patients with viral hepatitis. Furthermore, the 
ultrasound-based shearwave elastography is proposed for the routine clinical screening 
of patients with liver fibrosis. Finally, in an experimental rat study, a novel vectorized 
fibrin-binding magnetic resonance contrast agent was found to accurately detect liver 
fibrosis.  
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Palavras-Chave: Imagem por Ressonância Magnética, Imagem Ponderada em Difusão, 
Elastografia por Ressonância Magnética, Elastografia Supersónica por Onda de 
Cisalhamento, Fígado, Hepatites Virais, Doença Hepática Gorda Não Alcoólica, 
Quantificação de Gordura Hepática, Imagem  Molecular. 
 
Key words: Magnetic Resonance Imaging, Diffusion-Weighted Imaging, Magnetic 
Resonance Elastography, Supersonic ShearWave Elastography, Liver, Viral Hepatitis, 
Nonalcoholic Fatty Liver Disease, Liver Fat Quantification, Molecular Imaging. 
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1.1. Introduction 
 
Chronic liver diseases, such as viral hepatitis and nonalcoholic fatty liver disease 
(NAFLD) are a major cause of morbidity and mortality worldwide and their prevalence has 
been rising in the last two decades (1, 2). Although NAFLD was mostly unrecognized 
before the 1980’s, the rising epidemics of obesity and type 2 diabetes have brought 
awareness to this disease, which is currently considered the most common cause of chronic 
liver disease in the adult and paediatric population (1, 3). NAFLD includes a spectrum of 
liver damage ranging from bland steatosis to steatohepatitis, cirrhosis and ultimately liver 
failure and hepatocellular carcinoma (3).  
Liver biopsy, with histopathological scoring of the obtained specimen, is until now the 
reference standard to evaluate fibrosis, inflammation and steatosis (3). However, it’s an 
invasive technique and it’s also prone to sampling errors in diffuse and heterogeneous liver 
diseases such as viral hepatitis and NAFLD (4). Moreover, from a patient’s perspective the 
prospect of undergoing repeated liver biopsies for follow-up is intimidating and highly 
inconvenient.  
Noninvasive biomarkers are currently under demand and are of the utmost importance to 
assess liver fibrosis, inflammation and steatosis. Several noninvasive serum biomarkers, 
such as the FibroMax panel (FibroTest + SteatoTest + NASHTest), the plasma Pentraxin-3 
and Cytokeratin-18 are being studied, but their accuracy and clinical usefulness is yet to be 
determined and their utility in the follow-up is unknown (3). Diagnostic Radiology is a 
dynamic specialty that continues to undergo rapid changes with ongoing advancements in 
technology and has revolutionized several fields of medicine. Currently, imaging is as 
important, albeit complementary, as a detailed physical exam and anamnesis. The prospect 
of using noninvasive and radiation-free methods, like magnetic resonance imaging and 
25  
ultrasound, in the screening and follow-up of patients with liver fibrosis, inflammation 
and/or steatosis is particularly attractive. Thus, the purpose of this project was to determine 
which imaging biomarkers could be used in the noninvasive assessment and follow-up of 
fibrosis, inflammation and steatosis in patients with chronic liver diseases. 
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2.1. The Liver 
2.1.1. History 
The art of hepatoscopy started at Mesopotamia, approximately at the year 2000 BC, when 
the inspection of the liver was the most important method of foretelling events. The 
sacrificial priests acquired precise knowledge of the animal liver, especially that of the 
sheep, and assigned specific names to the different parts of the liver and gallbladder or their 
respective variations (5).  The reading of the liver received an enormous acceptance from 
the Greeks and Etruscans. Several Etruscan liver models have survived until our days in 
which the gallbladder, the pyramidal and papillary processes and the left and right lobes 
(pars hostilis and pars familiaris, respectively) are well differentiated (Fig.1) (5).  
 
 
 
 
Figure 1. Etruscan clay model of a liver (200 BC). Reproduced from [5]. 
 
 
The Etruscan fortunetellers were particularly notorious in the Roman Empire and 
prophecies were related to specific features in the sacrificial liver or gallbladder (Fig. 2) (5, 
6). For example, predictions pertaining to the inquirer were mostly derived from the 
appearance of the pars familiaris and gallbladder and those of the rival from the pars 
hostilis. Moreover, numerous predictions were of historical interest such as the presence of  
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an enlarged and double gallbladder that foresaw the victory of Octavian against the forces 
of Marcus Antonius and Cleopatra in the battle of Actium (31 BC) (5, 6).  At the time of 
the fall of the Roman Empire, hepatoscopy was already well established in the human 
belief and it was used to influence major personal and political decisions.  
 
 
Figure 2. Etruscan hand mirror in bronze, 
500–400 BC. KALCHAS, the most famous of 
the sacrificial priests, inspects the animal liver a 
with large caudate process. Reproduced from [5]. 
 
 
In the 5th and 6th centuries BC, the profound effect of mythology was replaced by rational 
research of anatomy and physiology. Aristoteles of Stagira was the first to distinguish 
between hepatic arteries and veins and to describe the portal vein within the venous system 
(5). Four hundred years later Galenos of Pergamon described the anatomy of the liver in 
greater detail than before, as he explained the ramifications of the intrahepatic vessels and 
sinusoids. It was only in 1654 that Francis Glisson published the first monography on the 
liver and discussed intrahepatic vessels and the surrounding connective tissue (Fig. 3) (5, 
7). Even today we refer to the Glisson’s capsule that surrounds the liver and to the portal 
triad as Glisson’s triangle.  
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Figure 3. Illustration of the blood and bile vessels of the 
liver by F. GLISSON, 1654 (A: dorsal region, B: right 
aspect, C: ventral region, D: left aspect, E: hepatic veins, 
H: umbilical vein, K: duct of ARANTIUS, G: gall bladder, 
I: bile duct, F: portal vein). Reproduced from [5]. 
 
 
Johan Jacob Wepfer first described the term lobule, in the liver parenchyma, in 1664, but it 
was with Marie François Xavier Bichat, the father of modern Histology, at the beginning 
of the 19th century that the hepatic parenchyma was considered to be a special tissue in 
terms of function and morphology (5). The French Physiologist Henri Dutrochet described 
hepatocytes twenty years later. In the following years, the development of the research 
methods brought greater insight into liver metabolism and physiology with such names as 
Claude Bernard and Friedrich Theodor Frerichs, the fathers of modern Liver Physiology 
and Pathology, respectively (5). 
 
 
2.1.2. General Liver Anatomy  
The liver is the largest solid organ in the human body and its volume ranges from 1,500-
1,600 cm3 in men and 1,400-1,500 cm3 in women (5). Its surface is smooth with a red  
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brownish color and the liver is located intraperitoneally, with the exception of its bare area.  
The separation between right and left liver is not macroscopically visible, however, the left 
(smaller) and right (larger) lobes can be easily discriminated at the level of the falciform 
ligament (Fig. 4). This double layer of peritoneum binds the liver to the anterior abdominal 
wall, and on its free edge we can find the round ligament, which is a remnant of the 
umbilical vein that carries the oxygenated blood to the foetus (8, 9).  
 
 
Figure 4. Normal liver. The falciform ligament separates the left and right lobes. Reproduced from 
IMAIOS. 
 
 
 
 
The liver has a dual blood supply from the portal vein and common hepatic artery. The 
portal vein is responsible for approximately 70 % and the hepatic artery for 30 % of the 
blood flow (9, 10). In the liver parenchyma, a fibrous sheath (Glisson’s capsule) surrounds 
arteries, portal veins, and bile ducts. However, hepatic veins lack such protection. 
The common hepatic artery takes origin most often from the celiac trunk (86 %); other 
sources are the superior mesenteric artery, aorta or left gastric artery. The common hepatic 
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artery then runs horizontally along the upper border of the head of the pancreas (9). When 
the gastroduodenal artery branches off the common hepatic artery, it continues as the 
proper hepatic artery and turns upward to ascend in the lesser omentum, enveloped by the 
hepatoduodenal ligament (9, 11). Within this ligament, the proper hepatic artery that lies to 
the left of the common bile duct and anterior to the portal vein, divides into right and left 
branches (Fig. 5) (10).  
The portal vein is formed by the confluence of the superior mesenteric vein and the splenic 
vein behind the neck of the pancreas (9, 10). At the liver hilum, the portal vein bifurcates 
into right and left branches before entering the liver. The right branch is short and rapidly 
divides into anterior and posterior branches for the anterior and posterior right sectors. In 
general, portal veins are found posterior to the hepatic arteries in their lobar and segmental 
distribution (10). 
Three major veins that open into the Inferior Vena Cava (IVC) drain the liver (Fig. 5). The 
right, median and left hepatic veins are found intrahepatically within planes separating 
lobes and sectors (8 - 10).  
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Figure 5. Normal anatomy of the liver. CBD: common bile duct, CD: cystic duct, CHD: common hepatic 
duct, HA: hepatic artery, IVC: inferior vena cava, LHA: left branch hepatic artery, LHD: left hepatic duct, 
LHV: left hepatic vein, LPV: left portal vein, MHV: middle hepatic vein, PV: portal vein, RHA: right branch 
hepatic artery, RHD: right hepatic duct, RHV: right hepatic vein, RPV: right portal vein. Adapted and 
reproduced from [9]. 
 
Bile canaliculi are formed by parts of the membrane of adjacent parenchymal cells, and 
they are isolated from the perisinusoidal space by junctions. Bile flows from the canaliculi 
through ductules (canals of Hering) into the interlobular bile ducts found in portal triads. 
Biliary segmentation is identical to portal vein segmentation (8 - 10). 
The hepatic lymphatic network, superficial and deep, does not follow the functional 
vasculobiliary organization (Fig. 6). The superficial lymphatic system, located within the 
Glisson’s capsule, travels toward the thorax and the abdominal regional lymph nodes. 
Lymph vessels pass the diaphragm mainly in the bare area or through Morgagni’s foramen 
to reach anterior or lateral phrenic nodes. The deep system is the system of greater 
lymphatic outflow. It drains toward the lateral phrenic nerve nodes through the caval hiatus 
following hepatic veins or to nodes of the liver hilum following portal vein branches (12). 
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Figure 6. Left: Superficial pathways of lymphatic drainage for the liver. The anterior diaphragmatic 
nodes consist of the lateral anterior diaphragmatic group and the medial group, which includes the 
pericardiac nodes and the subxiphoid nodes behind the xiphoid cartilage. The nodes in the falciform ligament 
drain into the anterior abdominal wall along the superficial epigastric and deep epigastric lymph nodes. The 
epigastric and the subxiphoid nodes drain into the internal mammary nodes. Right: Deep pathways of 
lymphatic drainage for the liver. The deep pathways follow the hepatic veins to the inferior vena cava 
nodes and the juxtaphrenic nodes that follow along the phrenic nerve. The pathways that follow the portal 
vein drain into the hepatic hilar nodes and the nodes in the hepatoduodenal ligament, which then drain into 
the celiac node and the cisterna chili. Reproduced from [12]. 
 
2.1.3. Segmentation of the Liver  
Functional anatomy refers to the description of hepatic segmentation, which is the genuine 
anatomical basis for modern hepatic surgery. Liver resection still remains the only 
potential curative treatment for primary and metastatic liver tumors, and it is also indicated 
in some benign liver conditions, such as symptomatic hemangiomas or adenomas. It was 
the constantly enhanced knowledge of hepatic anatomy that enabled improvements in the 
techniques of liver resection. The resection of the liver started at the beginning of the 18th 
century when, in 1716, Berta performed the first partial liver excision. However, the 
unstoppable bleeding and high mortality rates, made surgeons dread to operate on this 
organ, and the first successful liver resection was only performed at the end of the 19th 
century (7). The segmental and vascular anatomy that defines the surgical approach to 
lesion resection is the most important anatomy to liver imaging. Couinaud, developed a  
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numbering system in 1957 and was an innovator in this field, by showing two major 
advances (8, 13). First, liver can be subdivided in hemilivers, sectors and segments using 
venous landmarks: portal branches and hepatic veins. Second, each segment has its own 
hepatic artery, portal vein and biliary drainage and therefore can be removed or safely 
preserved. The eight Couinaud segments have separate vascular inflow, outflow, and 
biliary drainage and therefore can be resected without damaging the remaining segments. It 
was the work of Goldsmith and Woodburn (1957), Couinaud (1957) and Bismuth (1982) 
that led to the nomenclature used today (Table 1) (7, 14). From a practical and axial 
imaging perspective, division of the liver into segments is based on a very important 
concept of three longitudinal planes and two transverse planes (Fig. 7) (13). A longitudinal 
plane through the middle hepatic vein, IVC, and gallbladder fossa divides the liver into 
right and left hemilivers (Fig. 8). A longitudinal plane through the right hepatic vein 
divides the right liver into anterior (VIII and V) and posterior (VII and VI) sectors. A 
longitudinal plane through the left hepatic vein divides the left liver into medial (IVa and 
IVb) and lateral (II and III) sectors. The branches of the portal vein divide the liver into 
segments. A transverse plane through the left portal vein divides the left liver into superior 
(IVa and II) and inferior (IVb and III) segments. An oblique transverse plane through the 
right portal vein divides the right liver into superior (VIII and VII) and inferior (V and VI) 
segments (14, 15). Segment I is called the caudate (Spiegel’s) lobe and extends between 
the fissure of the ligamentum venosum and the IVC. In its inferior surface we can find the 
pyramidal (right) and papillary (left) processes. The hepatic venous drainage from the 
caudate lobe goes directly into the IVC via small veins. The ligamentum venosum or 
Arantius ligamentum that limits the caudate lobe is secondary to the obliteration of the 
ductus venosus that, during foetal development, connected the umbilical portion of the 
portal vein to the inferior vena cava, shunting away from the liver the oxygenated 
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umbilical cord blood. The right lobe includes all the segments in the right liver (VIII, VII, 
VI, V) and the segment IV. The left lobe corresponds to the left liver minus the segment 
IV, which means: segments II and III (Fig. 9) (7, 14, 15). 
 
Table 1. Anatomic segments of the liver  
 
Reproduced and adapted from [14]. 
 
 
 
 
Figure 7. Liver segmentation based on the venous plans. Segment 1 is located posteriorly. Reproduced 
from www.radiologyassistant.nl. 
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Figure 8. Longitudinal plane separating through the medial hepatic vein and gallbladder separating the 
right and left hemilivers Left: above portal vein bifurcation. Right: below portal vein bifurcation. I, 
caudate segment. Reproduced from www.sfrnet.org “Anatomie du foie et protocoles d’exploration: trucs et 
astuces pour la pratique”. 
 
 
 
 
Figure 9. Liver Segments. Reproduced from www.sfrnet.org “Anatomie du foie et protocoles d’exploration: 
trucs et astuces pour la pratique”. 
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2.1.4. Hepatic Lobules 
The liver parenchyma is divided into lobules. The classic lobule resembles a hexagon and 
is centered on a central vein with portal triads (which contain a branch of the portal vein, 
hepatic artery and bile duct) at each corner (Fig. 10) (16). The lobular structure also 
contains liver cells, called hepatocytes, arranged in plates around the central vein. The 
space between those plates of hepatocytes is filled with sinusoids (low pressure vascular 
channels lined with endothelial cells) that receive blood from terminal branches of the 
hepatic artery and portal vein at the periphery of the lobule and deliver it into central veins 
(Figs. 10, 11) (5, 16). Functionally, the lobule can be divided into three zones based on the 
oxygen supply. Zone 1 encircles the portal triads, which are well oxygenated by the hepatic 
arteries, while zone 3 is located around the central veins where oxygenation is poor. Zone 
2 is located in between (Figs. 12, 13) (17).  
 
 
Figure 10. The classic hepatic lobule. Reproduced from IMAIOS 
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Figure 11. Enhancement of Figure 10 at the level of two plates of hepatocytes. Reproduced from [17]. 
 
 
 
 
 
Figure 12. The hepatic lobule and acinus. The acinus is the physiological unit of the liver and is divided 
into three zones, according to distance from the afferent arterial supply. Reproduced from [17]. 
 
Between the sinusoidal endothelium and hepatocytes we can find the space of Disse. 
Sinusoidal endothelial cells are highly fenestrated, which allows unimpeded flow of 
plasma from sinusoidal blood into the space of Disse (5, 16). Therefore, hepatocytes are 
bathed in nutrient-rich plasma (derived from the small intestine), but this plasma will also 
flow back toward the portal triads, collecting into lymphatic vessels and forming a large 
fraction of the body's lymph. In fact, lymphatic vessels are also found in the portal triads 
but since their walls are delicate and often collapsed, they are less easily identified (5, 16). 
Another significant feature of hepatic sinusoids is that they house an important part of the 
phagocytic system, the Kupffer cells which are a type of macrophage (5). 
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Figure 13. Normal liver tissue. H: hepatocytes, P: portal vein, BD: bile duct, HA: hepatic arteriole. 
Reproduced from [5]. 
 
 
 
2.2.  Chronic Liver Diseases 
 
2.2.1. Chronic Viral Hepatitis 
Chronic hepatitis is not a single disease, but rather a clinical and pathological syndrome, 
which has several causes and is characterized by varying degrees of liver damage. For lack 
of a better definition of chronicity, chronic hepatitis is still defined as a disease that persists 
for at least six months (18, 19). The current classification of chronic hepatitis is based on 
the aetiology, activity of the inflammatory process (grading) and degree of fibrosis 
(staging). Globally, the most common aetiology of chronic hepatitis and cirrhosis is viral 
hepatitis B and C (18 - 20). Grading describes the necroinflammatory activity, which is 
based on the hepatocellular damage and inflammatory infiltration. Staging reflects the 
architectural alterations in the parenchyma that are due to fibrosis and cirrhosis (5). 
Fibrosis is characterized by an increase in collagen production (types I and III) and 
consequent deposition in the extracellular matrix, while cirrhosis represents the last stage 
of fibrosis progression. It is characterized by fibrosis, nodular regeneration of the liver 
parenchyma and vascular disturbance such as capillarization of the sinusoids and 
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intrahepatic shunts. The introduction of liver biopsy in the medical setting has 
revolutionized hepatology since the 1960s. Several semiquantitative systems, which are not 
directly comparable, have been proposed to assess chronic viral hepatitis and the most 
commonly used are the Ishak modification of the Knodell hepatic activity index and the 
METAVIR score (21). The latter, used in this project, stages fibrosis on a 5-point scale 
from F0 to F4 (cirrhosis), and grades activity on a 4-point scale from A0 to A3 (Table 2). 
A subclassification of cirrhosis was also proposed using the Laennec Scoring System that 
subdivides cirrhosis (F4) into F4 A (mild), F4 B (moderate) to F4 C (severe) (22). In 
chronic infection, the indication for treatment depends on the amount of fibrosis and aims 
to avoid the development of cirrhosis and hepatocellular carcinoma. The most clinical 
relevant end points are a fibrosis stage ≥ F2, which indicates the need for antiviral 
treatment, and the detection of cirrhosis (F4), which means that patients should be 
monitored for complications such as the development of portal hypertension and 
hepatocellular carcinoma (23). However, new triple therapy of HCV with increased 
response rates and decreased side effects may enlarge the indications for treatment to 
patients with < F2 fibrosis, making the detection of patients with ≥ F2 less crucial. Despite 
the widespread use of liver biopsy, there has been in the past decade an increased focus on 
its disadvantages. Apart from the invasiveness of the technique, which by itself carries 
risks, liver biopsy is subjected to sampling error (due to the small liver sample) and it 
suffers from intra- and interobserver variation (4, 21, 23). All these factors play an 
important role in its variability and highlight the fact that we are probably dealing with an 
imperfect gold standard. However, this perception has pushed even further the need to 
develop novel noninvasive biomarkers to screen and manage patients with chronic liver 
diseases. 
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Table 2. Metavir Scoring System 
 
Reproduced from www.ccr.fr. 
 
2.2.2. Nonalcoholic Fatty Liver Disease (NAFLD) 
Hepatocellular steatosis is a hallmark in NAFLD. Liver steatosis is characterized by lipid 
overload and is defined as more than 5% of hepatocytes containing fat (Fig. 14) (24, 25). 
In NAFLD liver steatosis is most often macrovesicular, which means that there is a single 
large fat droplet inside the cytoplasm pushing the hepatocyte nucleus to the periphery. The 
presence of microvesicular steatosis (multiple tiny droplets) is rare, never exceeding more 
than 16%, and is frequently associated with a more severe disease progression (26). The 
most used histopathological quantification of liver steatosis (grades 0 to 3) refers to the 
percentage of hepatocytes containing fat (< 5%; 5 – 33%; 33 – 66%; > 66%) (27).  
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Figure 14. Liver slice with macrovesicular steatosis in a diabetic patient. Reproduced from [5]. 
 
NAFLD includes a spectrum of disorders and it ranges from nonalcoholic fatty liver 
(NAFL) to nonalcoholic steatohepatitis (NASH), progressive liver fibrosis and cirrhosis 
(28 - 30). In Portugal about 27% of the population is estimated to have NAFLD, which is 
currently considered the worldwide leading cause of chronic liver diseases being closely 
related to the growing frequency of obesity and insulin-resistant type 2 diabetes (1, 29, 31 - 
33) (Figs 15, 16). The association of obesity and diabetes represents an added risk since in 
this case the prevalence of NAFLD, NASH and cirrhosis reaches almost 100%, 50% and 
19%, respectively (29). NAFLD represents not only a considerable loss in the individual 
quality of life but also an increase in disease-related absenteeism and healthcare costs (3, 
34).  
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Figure 15. Color map of NAFLD prevalence based on the average national prevalence (27%). 
Reproduced from [31]. 
 
 
Although early stages of liver steatosis may be reversible, still 25% of the patients with 
NAFL can progress to NASH, 50% of these will evolve to fibrosis and 10 - 29% to 
cirrhosis, ultimately leading to hepatocellular carcinoma (HCC) (24, 25). The evolution of 
steatosis, steatohepatitis, progressive liver fibrosis and cirrhosis is the result of a complex 
set of factors not yet fully understood. An inflammatory state has been associated with the 
development of NASH and liver damage, and a cytokine imbalance, in particular an 
increase in the ratio tumor necrosis factor-alpha/adiponectin, could be important in the 
development of NASH and correlate with disease severity, but the data available are 
limited (24, 29, 30).  Currently, noninvasive markers for NAFLD include clinical signs and 
symptoms, laboratory tests, ultrasound and various combinations of these methods. 
Although useful, they lack the specificity and sensitivity to differentiate NAFL from 
NASH patients (35). Most patients with this disease are asymptomatic at presentation and 
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liver enzymes values such as aspartate aminotransferase and alanina transaminase 
frequently oscillate between normal and five times the upper limit. There have been cases 
where the full histological spectrum of NAFLD is present even with normal serum levels 
(4, 29, 30, 33).  
 
 
Figure 16. The disease spectrum of nonalcoholic fatty liver disease. (A) Schematic of progression of 
NAFLD. The accumulation of TG within lipid droplets in hepatocytes causes steatosis. Steatosis associated 
with inflammation, cell death, and fibrosis is referred to as NASH, which can progress to cirrhosis. 
Individuals with cirrhosis have an increased risk of hepatocellular carcinoma. (B) Histological sections 
illustrating normal liver, steatosis, NASH, and cirrhosis. Collagen fibers are stained blue with Masson’s 
trichrome stain. The portal triad (PT), which consists of the hepatic artery, portal vein, and bile duct, and the 
central vein (CV) are shown. Reproduced from [24]. 
 
The existence of fibrosis is not required to diagnose NASH but a specific pattern of 
steatosis, hepatocyte hydropic ballooning (cell injury) and surrounding lobular 
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inflammation is essential (28). Although the presence of fibrosis does not represent a 
critical end point, the detection of fibrosis is by itself highly suggestive of NASH and is 
important to recognize. It should be noticed that in NASH adult patients the initial site of 
fibrosis (but also steatosis and ballooning) development is in acinar zone 3 while in viral 
hepatitides the initial fibrosis is portal and periportal (4, 27, 28). In 2005, the NASH 
Clinical Research Network (NASH CRN) proposed a scoring system (from 0 to 8) for 
disease activity based on the assessment of steatosis, ballooning and inflammation (Table 
3) (27, 36).  
 
Table 3. Nonalcoholic Fatty Liver Disease activity score 
 
Reproduced from [27]. 
 
Currently, the individual natural history of NAFLD is unknown and, unlike other chronic 
liver diseases, there are no algorithms to simplify its management and no specific 
pharmacological treatment (3, 36).  
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2.3. Noninvasive Techniques to Assess Liver Fibrosis, Inflammation and Steatosis  
 
To overcome the complications and limitations posed by liver biopsy, alternative 
noninvasive methods ranging from serum biomarker assays to advanced imaging 
techniques have been developed for the evaluation of liver fibrosis, inflammation and 
steatosis.  
Section 2.3.1. will briefly review current noninvasive serum biomarkers. In the next two 
sections noninvasive imaging modalities will hence be detailed. Section 2.3.2. will focus 
on imaging techniques not directly related to this project and the final section 2.3.3. will 
thereafter provide greater detail on Ultrasound-based Supersonic Shear Imaging and 
Magnetic Resonance, which are the basis for all studies presented in the current project. 
 
2.3.1. Noninvasive Serum Biomarkers  
Several noninvasive serum biomarkers have been studied to assess fibrosis, particularly in 
viral hepatitis C, which can be divided in direct and indirect markers of extracellular 
matrix remodeling. Amongst direct biomarkers we currently have hyaluronan, laminin, 
procollagen III, type IV collagen and YKL - 40, which have variable reported 
performances for the diagnosis of significant fibrosis. They all lack large-scale independent 
studies (Table 4) (23, 37). Among indirect serum biomarkers the most commonly used are 
the aspartate-to-platelet ratio and FibroTest. The latter combines five biochemical markers 
(haptoglobin, α2-macroglobulin, apolipoprotein A1, γ-glutamyltransferase and bilirubin). 
These biomarkers demonstrate greater utility in the detection of advanced fibrosis than 
intermediate and early stages, whose patients are more likely to benefit from therapeutic 
intervention. Moreover, they produce false positives in patients with hyperbilirubinemia  
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and elevated aminotransferases levels. In patients with viral hepatitis B noninvasive 
composite scores are not as well validated (21, 23). The accuracy and clinical usefulness of 
serum biomarkers to detect liver inflammation is yet to be determined. Although caspase-
cleaved cytokeratin-18 fragments have shown some promise to distinguish patients with 
NAFL from those with NASH (AUROC of 0.82 - 0.83) their use is still limited to clinical 
trials (38). A common flaw to these biomarkers is also that their utility in following disease 
progression is still currently unknown. 
 
Table 4.  Performance of different serum biomarkers to detect fibrosis stages ≥ F2 and F4  
 
AUC, area under the receiver operating characteristic curve; N/A, not available; AAR, AST-to-ALT ratio; 
APRI, AST-to-platelet ratio index; NPV, negative predictive value; PPV, positive predictive value. Adapted 
and reproduced from [37]. 
 
2.3.2. Overview of Imaging Techniques not Related to this Project 
 
- Liver Ultrasound 
Ultrasounds are sound waves traveling in pulses with frequencies higher than the ones 
audible by the human ear (> 20,000 Hz). Piezoelectric crystals in an ultrasound transducer 
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generate a pulse and ultrasound imaging depends on the reflection of those sound waves, 
which then become echos.  The ultrasound device processes the returning echos and 
assigns them a level of gray, somewhere between black and white, correlating to that 
signal's amplitude, or strength, and an image is immediately visible on a screen (39). 
Ultrasound is widely used in clinical practice to detect fatty infiltration of the liver. 
Steatosis increases liver echogenicity making the liver appear brighter than the cortex of 
the right kidney or the spleen (Fig. 17) (39). The initial stages of fibrosis may have very 
little effect on the ultrasound appearances of the liver, but at advanced stages the liver is 
more reflective, giving the appearance of a bright liver often with a coarse texture (40). 
The association of fibrosis with fatty changes further complicates the clinical picture, since 
both increase liver echogenicity. Ultrasound is unable to provide a precise grading and 
staging of steatosis and fibrosis, respectively. Moreover, its sensitivity is reduced in the 
morbidly obese patients and its performance is highly operator-dependent (35). 
 
            
Figure 17. Liver steatosis assessed by B-mode ultrasonography. The liver (circle) is brighter than the right 
kidney, represented at the inferior left corner of the image. 
 
 
 
Only few studies have used contrast-enhanced ultrasound and time intensity curve analysis  
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to assess NASH and liver fibrosis (41, 42). Iijima et al (41) showed that the accumulation 
of ultrasound contrast microbubbles in the liver parenchyma is decreased in patients with 
NASH but not NAFLD, which led to lower peak signal intensity and faster decrease in the 
measured signal intensity over time in NASH patients. However, the authors did not find 
any correlation between these measurements and fibrosis and steatosis as assessed by 
histopathology. In the work by Orlacchio et al (42) in patients with viral hepatitis C, a 
significant correlation was found between liver parenchyma peak signal intensity and 
fibrosis staging. Moreover, liver parenchyma peak signal intensity was able to distinguish 
patients with F1 vs F2 and F2 vs F4 fibrosis scores. However, intra- and interobserver 
agreement and technique reproducibility were not assessed in the study.  
 
- Transient Elastography (TE) 
The effectiveness of palpation as a diagnostic tool to detect disease has lead to the 
development of imaging techniques able to assess the changes in the mechanical properties 
of an organ, such as the liver, with increased fibrotic tissue. Transient elastography is a 
unidimensional ultrasound-based method that determines tissue stiffness by measuring the 
propagation of a shear wave in the liver. This device contains a transducer, used both as 
receiver and emitter, mounted on a mechanical vibrator that with a short, mild amplitude 
and low frequency (50 Hz) tone burst (transient) generates the shear wave. An important 
feature of this method is that the mechanical vibration has to be transient to avoid 
reflections and interferences occurring within the tissue (43). The stiffer the tissue, the 
faster this shear wave propagates. TE is rapid, easy to perform and painless, measuring 
liver stiffness in a cylinder of 1-cm wide per 4-cm long, around 25 - 65 mm below skin 
surface, which results in a tissue volume 100 times larger than the biopsy specimen 
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 (Fig. 18) (23, 44). Although the results are immediately available in kiloPascals (kPa), a 
cautious interpretation of data is needed and all the following conditions must be fulfilled: 
at least 10 valid measurements, a success rate (ratio of valid measurements to the total 
number of measurement) > 60% and an interquartile range (IQR; which reflects variations 
among measurements) of less than 30% of the median value (IQR/M, ≤ 30%) (Fig. 19). 
Uninterpretable data or failed examinations still occur in at least 16 - 20% of patients with 
a body mass index (BMI) ≥ 28 kg/m2, in patients with narrow intercostal spaces and in the 
presence of ascites (23, 44). Moreover, the measurement place is confined to the right liver 
edge, which limits the analysis of the liver parenchyma. 
 
 
Figure 18. Left: Probe positioning to measure liver stiffness with Transient Elastography. Right: 
Representation of the explored liver volume. Reproduced from [44] and from www.apef.com.pt 
(Associação Portuguesa para o Estudo do Fígado). 
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Figure 19. Measurement image for Transient Elastography. The result of 3.9 kPa indicates that the 
patient has an F0 fibrosis stage. Reproduced from www.jle.com/fr (“Le FibroScan®: un nouvel outil pour 
l’évaluation non invasive de la fibrose au coursdes maladies chroniques 
du foie”). 
 
Liver stiffness values measured with transient elastography have been well correlated with 
mild and severe fibrosis stages (AUROC 0.79 - 0.98) in a wide range of patients with 
chronic liver diseases, but its performance is limited for the intermediary stages of fibrosis 
(23, 45, 46). Moreover, fibrosis is frequently associated with other parenchymal changes 
and a significant increase in liver stiffness has recently been observed in in vivo and in 
vitro studies in the presence of edema, inflammation, steatosis and cholestasis (45 - 49). 
This overestimation of liver stiffness and the consequent fibrosis overstaging have very 
important clinical consequences in terms of treatment and patient follow-up. 
 
- Accoustic Radiation Force Impulse (ARFI) 
Acoustic radiation force impulse imaging is a radiation force-based imaging method that is 
provided by conventional B-mode ultrasonography. ARFI imaging involves transmission 
of an initial ultrasonic pulse, at diagnostic intensity levels, to obtain a baseline signal for 
later comparison. An acoustic pushing pulse with short-duration (0.3 msec) and high-
intensity is afterwards transmitted by the same transducer. This induces a shear-wave that  
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propagates away from the region of excitation and generates localized displacements in the 
tissue, which are measured by a series of diagnostic intensity pulses (43). The propagation 
speed of the shear wave (m/sec) is measured in a cylinder of 10-mm long per 6-mm wide, 
which is smaller than the one for transient elastography, but has the advantage of being 
chosen by the operator who is able to place it avoiding large vessels or liver lesions (Fig. 
20) (23). ARFI demonstrates a stepwise increase in mean velocity with increasing fibrosis 
stages. The diagnostic accuracy (AUROC) for the detection of mild and severe fibrosis was 
found to vary between 0.74 - 0.98 (50). In several studies ARFI was as accurate as 
transient elastography for the assessment of patients with severe fibrosis, but it should be 
noted that in one of these studies patients in the control group had velocities in the cirrhotic 
range (23, 38, 44, 51, 52).  As opposed to TE this method can be implemented on regular 
ultrasound equipment, the region of interest is chosen by the operator and overcomes the 
reported limitations for TE such as ascites and obesity (23). However, ARFI still requires 
further validation in larger cohorts of patients and with diverse chronic liver diseases. 
 
 
Figure 20. Measurement window for ARFI elastography. Reproduced from www.intechopen.com. 
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- Computed Tomography (CT) 
Multidetector CT systems use x-ray tubes and x-rays detectors around the patient.  CT 
measures the attenuation of the liver, which can be expressed as an absolute value (in 
Hounsfield Units), or a ratio, by comparing it to that of the spleen. At unenhanced CT, the 
normal liver has a slightly greater attenuation than the spleen and intrahepatic vessels are 
visible as hypoattenuating structures (Fig. 21). Liver steatosis is diagnosed if the measured 
liver attenuation is at least 10 HU less than that of the spleen. In severe liver steatosis, the 
intrahepatic vessels appear hyperattenuated relative to the liver tissue (Fig. 22). A 
measured liver-to-spleen attenuation ratio of less than 1 is indicative of fatty liver (35, 40, 
53). However, liver attenuation is influenced by other factors such as edema, fibrosis, iron 
and copper and glycogen, which induce errors in fat quantification. Furthermore, the 
concomitant presence of liver steatosis and iron will induce opposite effects on liver 
attenuation. Thus, this technique has a poor performance as a screening tool, particularly in 
patients with mild steatosis (40, 53).  
 
 
Figure 21. Normal appearance of the liver at unenhanced CT. The attenuation of the liver (66 HU) is 
slightly higher than that of the spleen (56 HU), and intrahepatic vessels (v) appear hypoattenuated in 
comparison with the liver. Reproduced from [40]. 
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Figure 22. Diffuse fat accumulation in the liver at un- enhanced CT. The attenuation of the liver (15 HU) 
is markedly lower than that of the spleen (40 HU). Intrahepatic vessels (v) also appear hyperattenuated in 
comparison with the liver. Reproduced from [38]. 
 
Dual-energy CT with different tube potentials (140 and 80 kVp) can however present some 
advantages in the evaluation of liver steatosis, since the steatotic liver has more strikingly 
attenuation changes than normal liver with the different tube potentials (Fig. 23) (54). The 
attenuation difference is between 1.7 – 5.8 HU in mildly steatotic liver, 5.9 – 9.9 HU in 
moderately steatosis and more than 10 HU in the severely steatotic liver. However, this 
difference is attenuated in livers with concomitant iron and fat deposition (54).   
 
 
Figure 23. Dual-energy CT evaluation of liver in a 45-year-old male potential donor for living 
transplantation. Axial unenhanced CT scans obtained at 140 kVp (left image) and 80 kVp (right image) 
show a hepatic attenuation difference of 9 HU, a finding indicative of moderate hepatic steatosis. Reproduced 
from [54]. 
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Recently, CT was found to be useful in the assessment of liver inflammation and mild to 
moderate fibrosis in patients with chronic liver diseases. The measurements of the xenon 
solubility coefficient and portal venous tissue blood flow, with xenon-based computed 
tomography, were able to discriminate between patients with simple steatosis and 
advanced NASH (i.e., presence of bridging fibrosis) (55). Additionally, the measurement 
of the mean transit time with perfusion CT was found to have an early increase in patients 
with fibrosis but the performance of this parameter to dichotomize patients with F1 vs F2-3 
fibrosis stages was only moderate (56, 57).  The studies with CT not only need further 
validation but also expose the patients to ionizing radiation.  
 
2.3.3. Imaging Techniques used in the Current Project 
 
- Real-time ShearWave Elastography (SWE) 
Liver stiffness measured by ultrasound-based methods can be described in both physics 
and mechanics as the Young’s modulus (E), which represents the mechanical response of 
the liver to the shear stress and is expressed in kiloPascals (kPa) (43). In contrast to 
transient elastography that creates a transient excitation with a low frequency wave of 50 
Hz, shearwave elastography uses radiation force with a large frequency bandwidth, from 
60 to 600 Hz (“shear wave spectroscopy”), which allows a more precise analysis of the 
mechanical behavior in the tissue. The ultrasound probe of the device creates a “supersonic 
mach cone” in the liver as ultrasounds are focused successively at different increasing 
depths (10 mm apart), almost simultaneously and perpendicular to the patient’s skin (Fig. 
24). The different spherical waves generated by each focus, interfere along this “mach 
cone” and create a conical shear wave front on both sides of the focal points propagating at 
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a speed of 2 m/s (Fig. 24) (43, 58, 59).  
 
    
Figure 24. Left Image: generation of the Mach Cone shear waves from pushing beams at increasing 
depths. Right Image: Propagating velocities of the shear waves (2 m/s) and pushing beams (6 m/s). 
Adapted and reproduced from [58, 59]. 
 
The progression of the shear waves is captured by the very rapid acquisition ultrasound 
imaging system with good temporal resolution, typically up to 20,000 frames per second 
(i.e., Supersonic Shear Imaging). With this method the operator easily chooses the region 
of interest (ROI) in the liver for specific measurements. This ROI tool, “Q-box”, allows 
measuring an area that ranges from 1 to 7 cm2 up to 7 cm below the Glisson’s capsule (Fig. 
25) (58, 60).  The propagation speed of the shear wave is displayed in the monitor of the 
ultrasound device, on a pixel-by-pixel-based colour map at the same time as a B-mode 
image. For each one of the pixels of the colour map there is a corresponding stiffness 
value. The operator is able to assess the stiffness colour of a specifically chosen liver 
region and obtains the mean stiffness value and standard deviations for that same area (Fig. 
25).  One important advantage of this ultrafast imaging (it takes only a few milliseconds), 
is that neither patient nor operator movements will influence the measured liver stiffness. 
Moreover, as opposed to ARFI, which only evaluates elasticity at a focal point, SWE 
assesses elasticity using a shear wave front as explained previously (Table 5). 
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Table 5. Characteristics of the quantitative elastography techniques 
 TE ARFI SWE 
ROI chosen by 
operator 
N Y Y 
Shear wave 
generation mode 
Mechanical vibration Radiation force Radiation force 
Frequency 50 Hz Wideband Wideband 
Real-time images N Y Y 
Possibility to 
evaluate lesions 
N Y Y 
Influenced by 
ascites and obesity 
Y N N 
 
N, no; Y, yes; TE, Transient Elastography; ARFI, Accoustic Radiation Force Imaging; SWE, ShearWave 
Elastography. 
 
 
 
        
Figure 25. Measurement window for ShearWave Elastography. 
 
Only one study compared real-time SWE with TE and used liver biopsy for all patients as 
the reference standard (60) The authors found that SWE could more accurately 
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discriminate patients with a fibrosis stage F0-1 vs ≥ F2 (AUROC 0.92 vs 0.84, P = 0.002; 
SWE vs TE, respectively). However, the difference between both methods was not 
significant for patients with a F3 fibrosis stage or cirrhosis (AUROC 0.98 vs 0.96, P = 0.14 
- 0.48; SWE vs TE, respectively). The resulting cut-offs for SWE derived from this work, 
according to the fibrosis stages, are shown in table 6. This work included patients with 
chronic hepatitis C and low prevalence of obesity. This method still requires further 
validation in the clinical setting.  
 
Table 6. Median values obtained for each fibrosis stage with SWE and TE 
 
IQR, Interquartile range; kPa, kiloPascals; P values refer to differences between consecutive fibrosis stages 
(*F0-F1 versus F2; **F2 versus F3; ***F3 versus F4). Reproduced from [60]. 
 
- Magnetic Resonance Imaging (MRI) 
a. Basic Concepts and Physical Principles 
The human body is approximately 70% water and MRI uses the signal from these 
Hydrogen (1H) protons to generate images. The proton rotates around is own axis and since 
it has an electrical charge it behaves live a small magnet, called the magnetic moment. 
When protons are exposed to an external magnetic field (B0) they align in with the 
direction of the field and start to wobble, which is called precession (Figs. 26 - 28). The 
precession occurs at a characteristic frequency (Larmor Frequency), which is directly 
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proportional to the strength of the external magnetic field and is given by the Larmor 
equation (61, 62): 
 
ω0 = γH B0  / 2 π                                      [Equation 1] 
 
where, ω0 is the Larmor frequency (MHz), γH the gyromagnetic ratio specific to the 
hydrogen nucleus (42.58 MHz T-1) and B0 the strength of the magnetic field in Tesla (T).  
 
  
Figure 26. Random alignment of spins without an external magnetic field. Image reproduced from 
IMAIOS. 
 
Hydrogen protons have a Larmor frequency of 63.9 MHz at 1.5 T. When the spins suffer 
the influence of B0, and according to the classical theory, they tend to align into a parallel 
and anti-parallel manner. However, the parallel alignment is slightly prefered because the 
spins reside in a more favorable energy state. The difference between both alignments 
creates the net magnetization vector (NMV) or longitudinal magnetization that increases 
with higher field strenghts (Fig. 27) (61). This also happens in the earth’s magnetic field 
but the resulting longitudinal magnetization is considerably weaker than the one in an MR 
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unit. 
 
Figure 27. Alignment of spins: parallel and antiparallel with an external magnetic field. Reproduced 
from [62]. 
 
  
Figure 28. The wobbling spin is frequently compared to a spinning top. Images reproduced from 
IMAIOS. 
 
At this time the system is at equilibrium. When we apply a radiofrequency pulse (RF), by 
means of a coil, with exactly the same frequency as the proton Larmor frequency, we 
create the resonance condition. At this time spins are at an excited state and with a 90º 
pulse, all the longitudinal magnetization is flipped into a transverse plane (Fig. 29). The 
resulting magnetization is now called transverse magnetization. Whenever transverse 
magnetization is present, it rotates around its axis and induces a voltage in a receiver coil 
creating the MR signal (Fig. 30) (61, 62). 
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Figure 29. Transverse magnetization in the XY plane after the RF pulse. Image reproduced from 
IMAIOS. 
 
 
Once the RF pulse is turned off the MR signal rapidly starts to fade away. Two 
independent processes (spin-lattice and spin-spin interaction) decrease transverse 
magnetization and induce a return to the initial equilibrium energy state, while recovering 
longitudinal magnetization (61, 62).  
 
 
 
Figure 30. Coils transmit the MR signal. This signal is rapidly decreased due to the decay in transverse 
magnetization and the consequent increase in longitudinal magnetization (return to a stable energy state in 
axis Z). Images reproduced from IMAIOS. 
 
Longitudinal relaxation is the recovery of the net magnetization vector along the Z axis. 
This recovery is exponential in time, with a characteristic time T1 (longitudinal relaxation 
time). Dissipating the spins energy into the surrounding medium makes the return to the 
initial equilibrium energy state and this process is called spin-lattice interaction.  
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Transverse relaxation is the decay of transverse magnetization in the XY plane. This decay 
is exponential in time, with a characteristic time T2 (transverse relaxation time). The 
energy exchange for this process is due to energy transfer between spins (spin-spin 
interaction). This process is called T2 recovery.  However, inhomogeneities of the external 
magnetic field (caused by insufficient magnet shimming, the magnetic field generator and 
the patient being imaged) further contribute to the decay of the transverse magnetization 
and the sum of the two processes leads to T2* recovery. Thus, the exponential loss of MR 
signal is caused by T2* effects, and is called the free induction decay (FID) (61, 62).  
The T1 and T2 relaxation times are intrinsic MR image contrast parameters and depend on 
the tissue of interest that is being imaged. They represent the time it takes to recover or 
reduce 63% of the longitudinal and transverse magnetizations, respectively. 
Repetition time (TR) is the length of the relaxation period between two excitations pulses 
and therefore determines how much T1 recovery occurs in a particular tissue (Fig. 31). By 
choosing a short TR (< 600 ms) we increase T1-weighting i.e., the image contains mostly 
T1 information. Indeed, tissues with short T1 relax quickly and give a large signal (are 
bright) after the next RF pulse, while tissues with long T1 suffer very little relaxation and 
have less signal available (are dark) for the next excitation. Nuclei in fat tissue dissipate 
their energy to the surrounding medium very fast and have a short T1, but water takes a 
longer time to do it and therefore has a longer T1 (Table 7) (61, 62). 
The Echo time (TE) is the interval between the application of the excitation pulse and the 
collection of the MR signal. TE determines how much T2 decay occurs in a particular 
tissue. If a short TE (< 30 ms) is chosen, the differences in signal between tissues will be 
very small since T2 decay has just started and the image will have a low T2 weighting 
(Fig. 32) (61, 62). However, a longer echo time will enable detection of different signal 
intensities in the tissues. Tissues with a long T2 will produce a stronger signal and appear 
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bright. 
 
 
 
Figure 31. T1 differences between fat and water, according to the chosen short or long TR. 
Reproduced from [62]. 
 
 
 
Figure 32. T2 differences between fat and water, according to the chosen short or long TE. 
Reproduced from [62]. 
 
 
 
A short TR and short TE sequence is usually called T1-weighted. A long TR and long TE 
sequence is usually called T2-weighted. In proton density-weighted images (PD) 
differences in the number of hydrogen protons in the tissues have to be demonstrated. To 
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reduce both T1 and T2 effects these sequences have a long TR and short TE. 
 
Table 7. T1 and T2 relaxation times of different tissues at 1.5 T 
 
Note: T1 and T2 values shown for water represent the measured values in pure water and not water in 
biologic tissues. Reproduced from IMAIOS. 
 
 
The selective excitation of a desired slice and identification of a signal origin will rely on 
the fact that the Larmor frequency is proportional to the magnetic field strength. The 
magnetic field is first made inhomogeneous by means of additional magnetic fields 
(gradients) applied in a specific direction. As a result, the magnetic field strength has a 
smooth change and each slice has now its own specific Larmor frequency. Therefore, the 
application of a RF pulse with the same frequency as the one of the desired slice, will only 
excite protons in that area leaving all the others unaffected (Fig. 33) (61, 62). 
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Figure 33. Slice selection. After applying the gradient, the magnetic field changes gradually and 
each slice has its own Larmor frequency. The magnetic field strength as a difference of 10 G between slice A 
and B. 1 T equals 104 Gauss (G). Reproduced from [62]. 
 
 
 
Spatial encoding identifies the spatial positioning of the MR signal and it involves two 
important steps: phase and frequency encoding. Each one of this steps uses a specific 
gradient, either phase or frequency-encoding gradient, that induces phase and frequency-
shifts between the spins. All the collected data are stored in a mathematical area called the 
K-space that has a phase and frequency axis (Fig. 34). An MR image will be created after 
applying the Fourier transform to the raw data. Data-points in the center of the K-space 
determine contrast while those in the periphery determine the spatial information of the 
resulting images (63). 
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Figure 34. Graphical representation of the K space. Reproduced from [62]. 
  
 
The signal-to-noise ratio (SNR) is the relationship between the MR signal and the amount 
of noise in the image. A high SNR is desirable in clinical imaging. Parameters related to 
the MR unit field strength, emitter/receiver coils and sequence are able to increase or 
decrease the final SNR (Table 8).  
 
Table 8. Parameters affecting signal-to-noise ratio (SNR)  
 
  
FOV, field of view (distance across an image); Nex, number of averages. Reproduced from [61]. 
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b. Basic Pulse Sequences 
The Spin Echo (SE) pulse sequence uses a 90º pulse for excitation which changes all the 
magnetization into the XY plane, as previously explained. The transverse magnetization 
decays because some spins precess at a faster rate than others so after half the echo time a 
180º pulse is applied to refocus (“reverse”) the spins. At this time, those who were behind 
are now ahead and vice versa, and at the second half of the TE all spins will be again in 
phase. At this moment the echo is formed (Fig. 35). Since the 180º RF pulse eliminates de 
effect of field inhomogeneities but cannot compensate for the spin-spin interaction the 
signal decay is of the T2 kind. The spin echo sequence is characterized by an excellent 
image quality but long scan time (61 - 63).  
 
 
 
Figure 35. SE sequence. The excitation pulse always has a flip angle of 90°; the dephased spins are 
refocused into the spin echo by the 180° pulse. The dashed lines indicate the phase-encoding steps. 
Reproduced from [61]. 
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The gradient echo sequence (GRE) uses gradient coils, rather than pairs of RF, to produce 
the dephasing and rephasing of spins (Fig. 36). A major advantage of using gradients and 
not the 180º RF pulse, is that a very short TR can be used, which allows faster imaging 
compared to the SE sequence.  Since the static field heterogeneities are not corrected by 
the 180º RF signal decay is of the T2* kind (61 - 63). 
 
 
 
Figure 36. Gradient echo sequence. For the sake of simplicity, a flip angle α of 90° is assumed here as well. 
Reproduced from [61]. 
 
 
At this time a brief explanation is required about in-phase and opposed-phase GRE 
imaging, since this method has been used to detect liver fat for more than 25 years. The 
Larmor resonance frequency of fat protons is slower than that of water protons and they 
have a gap of approximately 210 Hz at 1.5 T (25, 64, 65). As shown in Figure 36 the two 
vectors in the transverse plane dephase with time and they will be in opposed-phase at half 
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the cycle and in-phase at the end of the cycle. The corresponding TE can be calculated 
according to the formula (25): 
 
TEn =  n / 2 x CSwater-lipids x ω0   [Equation 2]  
 
Where TE is the echo time, CSwater-lipids is the frequency gap between water and lipids and 
ω0 is the Larmor frequency (MHz). These theoretical calculations show that water and fat 
peaks are in-phase (IP); i.e., the signals are summed (IP = Water + Fat) and in opposed-
phase (OP); i.e., the signals cancel each other out (OP = Water - Fat) at 4.6 and 2.3 ms, at 1.5 
T, respectively (25, 65). The signal from the fat fraction (FF) can be calculated with 
equation [3]: 
 
FF = Fat / Water + Fat        [Equation 3] 
 
Where Fat is the signal from fat and Water the signal from water. We can nonetheless 
rearrange the terms of this equation and fat fraction can therefore be calculated as follows: 
 
FF = IP - OP / 2 x IP        [Equation 4] 
 
However, when performing this standard measurement (two echoes and high flip angle) 
errors are introduced in the final result because the T1 weighting of fat and the different 
T2* relaxations for water and fat are not taken into account. For greater detail please refer 
to chapter IV. 
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c. 
1H Magnetic Resonance Spectroscopy in the Liver (MRS) 
Magnetic resonance spectroscopy can record proton signals as a function of their resonance 
frequency and is able to detect metabolites present in tissues at very small concentrations. 
MRS is currently considered the imaging reference standard for liver fat quantification and 
is extremely sensitive to even trace amounts such as 0.5% (65 - 67). The resonance 
frequencies of water and fat protons are distinct, which translates into different positions in 
the overall peak spectrum, and are expressed as a shift in frequency, in parts-per-million 
(ppm), relative to a standard. The area under each peak is used to calculate the metabolite 
concentration within a given voxel of tissue. Triglycerides are spectrally complex and have 
at least six different peaks: the dominant methylene peak (CH2; 1.3 ppm), the methyl peak 
(CH3; 0.9 ppm) and the 2.8, 2.1, 4.2 and 5.3 ppm peaks  (Fig. 37) (66, 68). Measurements 
of the total lipids, frequently includes only the methylene peak (70 % of total fat peaks) or 
the methylene plus the methyl peaks (70% + 8%, respectively, of total fat peaks), because 
the 5.3 ppm peak overlaps with the one of water and the others are difficult to individualize 
at clinical field strengths (Fig. 38) (68). Water peak is located at 4.3 ppm (66, 68). 
 
Figure 37. Representation of typical triglyceride molecule. The chain shown is linoleic acid. R indicates 
the other fatty acid chains in the triglyceride. Several resonances (at 5.29 and 5.19 ppm; 2.20 and 2.02 ppm; 
1.6 and 1.3 ppm) are not resolvable in vivo at clinical field strengths (≤ 3 T) and appear as single peaks. 
Reproduced from [68]. 
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Figure 38. Left: coronal section of upper abdomen showing the region within the upper right hepatic 
lobe, in which measurement of liver triglycerides was obtained. Middle: proton spectrum from the 
liver, showing resonance peaks derived from hepatic water and triglycerides. Right: expanded view of 
the spectrum, highlighting resonances from protons of methylene (CH2), and methyl (CH3), in the 
fatty acid chains. Reproduced from [67]. 
 
MRS is technically challenging and to compensate for the low SNR, spectra are usually 
obtained from tissue volumes at least twice as larger than the voxels of water-based MRI 
and by repetitive signal averaging. Major drawbacks of this method are a substantially 
lower spatial resolution than the one for MRI and the longer time required for 
examinations and data post-processing (69).  
MRS in the liver is usually performed as a single voxel technique (66). The main 
advantage is that the sampled volume is larger and therefore the SNR is increased.  The 
two most commonly used spectroscopic sequences in the liver are the stimulated-echo 
acquisition mode (STEAM) and point-resolved spectroscopy (PRESS). In STEAM, a cubic 
voxel is generated with three orthogonal section-selective 90º pulses (Fig. 39). PRESS uses 
a 90º pulse followed by two 180º pulses (66, 69). Several studies compared the clinical 
performances of these two sequences. The volume of interest with STEAM is larger than 
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the one selected with PRESS and STEAM is also somewhat less sensitive to the J-coupling 
(i.e., interaction between spins within a molecule - also called spin coupling - which could 
cause these sequences to give different peak amplitudes). However, in STEAM only part 
of the available signal is used to produce the stimulated echo, thus PRESS has a higher 
SNR (by a factor of 2). There are still no specific recommendations as for the use of one or 
the other (66, 69 - 72).  
                              
Figure 39. A 3D localized volume (voxel) is formed at the intersection of three orthogonal slices.  
Reproduced from [72]. 
 
Although MRS is the imaging gold standard for liver fat quantification it has several 
limitations. First, it has limited spatial coverage, allowing measurements only at the voxel 
site. Second, it does require substantial expertise for its practical implementation. Third, 
even with automated post-processing it is still time-consuming in the busy clinical setting. 
Therefore, MRS is mainly limited to research and academic centers. 
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d. Intravoxel Incoherent Motion Diffusion-Weighted Imaging (IVIM DWI) 
Diffusion reflects the random Brownian motion of water due to thermal agitation. At 37 ºC 
the water molecules have an average displacement of 30 micrometers during a 50-
millisecond interval. This movement in biologic tissues suffers from the interaction of 
water molecules with cells, hydrophobic membranes, macromolecules (e.g. collagen in 
liver fibrosis) and vessels that will disturb free motion. Therefore the resulting diffusion is 
called apparent (ADC: apparent diffusion coefficient), and is considerably less than in pure 
water (73 - 76).  
The original pulse sequence was based on a spin echo sequence that has symmetric 
diffusion sensitizing gradients inserted before and after the 180º refocusing pulse (Fig. 40). 
Water spins experience a dephasing induced by the first diffusion-sensitizing gradient and 
afterwards rephasing by the second gradient (74). The derived signal of stationary water 
spins is maintained as practically unaltered as the spins are at the same position during the 
two diffusion-sensitizing gradients. However, moving water spins will be in different 
positions and are not perfectly rephased by the second gradient, so the derived signal is 
reduced. The degree of water motion is proportional to the signal attenuation. 
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Figure 40. The Stejskal-Tanner pulsed field gradient (1965), is the default diffusion sensitive sequence. 
Two diffusion-sensitizing gradients inserted before and after 180º RF refocusing pulse using precisely 
controlled duration and distance. G, amplitude; δ, duration of the sensitizing gradient; ∆, time between the 2 
sensitizing gradient lobes. Reproduced from [74]. 
 
 
Echo-planar imaging (EPI) is the gold standard DWI (diffusion-weighted imaging) 
technique. EPI is an ultrafast acquisition that uses oscillation gradient reversals to generate 
“odd” and “even” echoes that take significantly less time to be generated. Since EPI 
sequences are very sensitive to off-resonance effects of water and fat protons they are 
usually fat suppressed. Since liver is an isotropic organ (uniform in all directions) liver 
DWI uses tridirectional (x, y and z axis) diffusion gradients to calculate the average DWI 
image. The b-value provides diffusion weighting for DWI images. The higher the b-value, 
the more diffusion-weighted the image will be (low SNR), while at low b-values (< 100 
s/mm2) perfusion effects will dominate over diffusion weighting (high SNR) (76). ADC 
can be calculated as the slope of the signal attenuation as a function of b, expressed by the 
following equation using a mono-exponential fit (76). 
 
Sb/S0 = exp (-b ADC)         [Equation 5] 
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where ADC (10-3 mm2/s)  is the apparent diffusion coefficient, Sb the signal intensity for 
each b value and S0 the signal intensity at b0.  
The term intravoxel incoherent motion (IVIM) was first introduced in the clinical practice 
by Denis le Bihan in 1986, and translates the motion of water molecules at the voxel level, 
both intra- and extracellular but also in the capillary network.  This theory allows the 
separation and measurement of pure diffusion and perfusion-related diffusion coefficients 
(Fig. 41). According to the IVIM theory, signal attenuation as a function of b is expressed 
by the following equation using a bi-exponential fit (76, 77): 
 
Sb/S0 = (1-f) exp (-b D) + f exp (-b (D + D*))         [Equation 6]  
 
where Sb is the signal intensity for each b value, S0 the signal intensity at b0, f (%) the 
fraction of diffusion linked to microcirculation, D (10-3 mm2/sec) the true diffusion 
coefficient,  and D* (10-3 mm2/sec) the perfusion-related diffusion coefficient. 
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Figure 41. Plots show logarithm of relative signal intensity versus b value from normal liver 
parenchyma. Note that there is initially steeper decrease in plotted signal values (circles) at low b values 
(within rectangular box A) compared with more gradual attenuation of signal at higher b values (within 
rectangular box B). By applying intravoxel incoherent motion (IVIM) analysis, biexponential behavior of 
signal attenuation is characterized (solid line), resulting in typical hockey stick appearance of fitted curve. 
Using simple monoexponential apparent diffusion coefficient (ADC) line fitted to data (dotted line) in this 
case provides suboptimal characterization of signal attenuation behavior. Reproduced from [77]. 
 
At high b-values (> 100 - 200 s/mm2), the influence of D* on the signal decay is almost 
negligible and equation [6] can be simplified. D can therefore be calculated with a simple 
monoexponential fit (76, 77): 
 
Sb/S0 = exp (-b D)         [Equation 7] 
 
It has recently been recommended to calculate ADC using at least 2 b values > 100 s/mm2 
to avoid the perfusion effects. In this case, equations [5] and [7] become equivalent and the 
apparent diffusion coefficient equals the pure diffusion coefficient.  
DWI performed with a b-value of 0 s/mm2 corresponds to a T2-weighted sequence because 
S0 is proportional to exp (-TE/T2) (78). Thus, diffusion images have a T2 contamination 
and regions/structures with a long T2 may have an artificial signal enhancement known as 
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the T2 shine-through artifact. This can be overcome by using exponential images that are 
simply the diffusion image divided by the b = 0 image or by viewing the ADC map whose 
contrast represents the calculated ADC. 
DWI has been used to assess liver fibrosis and inflammation (79 - 86).  In fact, liver 
fibrosis is characterized by the accumulation of collagen, proteoglycans and other 
macromolecules in the extracellular matrix as a consequence of chronic injury and water 
molecules are hence expected to have restricted diffusion. Several studies reported that 
ADC was lower in cirrhotic than in non-cirrhotic livers and that it could be used to 
differentiate severe from mild stages of fibrosis. However, ADC was not reliable in 
distinguishing F0 from F1 and F1 from F2 fibrosis stages (80, 85, 86). Furthermore, one 
experimental and two clinical studies, the latter using IVIM, have reported that the 
decrease in ADC could be due instead to specific decreases in liver perfusion, which occur 
with increasing liver fibrosis (82, 83, 87).  
Only few studies addressed the influence of increasing inflammation grades in ADC 
measurements and with conflicting results. Taouli et al (81) found that patients with liver 
inflammation grades ≥ 1 and ≥ 2 had significantly lower ADCs when compared to patients 
without inflammation or with inflammation ≤ 1, respectively, and that ADC had a 
significant inverse correlation with the inflammation grade (r = - 0.543, P = 0.0001). 
However, Bonekamp et al (85) only reported a very weak correlation between 
inflammation and ADC (r = - 0.23, P = 0.03) and no significant independent influence for 
inflammation on the ADC.  
These diverging results and the scarcity of IVIM studies have opened the door to new 
discoveries in the relationship between diffusion/perfusion parameters and other 
parenchymal changes besides fibrosis, such as steatosis and inflammation, in patients with 
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chronic liver diseases.  
e. Magnetic Resonance Elastography of the Liver (MRE) 
MRE was first described in 1955 and along with the initial work in the 1990s this 
technique has now become very useful in the assessment of liver fibrosis (88). MR-based 
elastography uses a harmonic mechanical vibration of low frequency (typically between 50 
to 80 Hz) induced by an external transducer, to obtain information about the mechanical 
properties of the liver. This excitation generates compressional waves in the liver 
parenchyma and shear waves are obtained by mode conversion at tissue interfaces. 
Sinusoidal motion-encoding gradients at the same frequency as the vibration frequency are 
applied during image acquisition. The resulting phase-contrast images are processed with 
an inversion algorithm to generate viscoelastic maps or the elasticity can be calculated 
from the wave speed as done with ultrasound elastography (76, 88, 89). Usually, the 
viscoelastic properties at MRE are based upon spatial derivatives of the measured 
displacement fields and not on the shear wave speed. The shear properties of an organ, 
referred to as the shear modulus (|G*|, kPa), calculated by demodulation and local 
inversion of the linear viscoelastic 3D wave equation, are best described as a complex 
number composed of a real part, the storage modulus (G’, kPa) and an imaginary part, the 
loss modulus (G’’, kPa) (90). The former is determined by the elastic properties (return of 
the organ to the initial position), whereas the latter is associated with the viscous properties 
of the organ (tissue friction and attenuation of waves). Thus, G’ and G’’ are distinct from 
one another and may respond differently with respect to the underlying pathology.  
The complex shear modulus measured by MRE is not directly interchangeable with the 
Young’s modulus (E) measured with transient elastography, as explained by the following 
equation (91 - 93):   
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E = 2 (1+ σ) x ρ (λ x ϒ)2       [Equation 8] 
 
Where E is the Young’s modulus, σ the Poisson’s Ratio, ρ the density, λ the wavelength 
and ϒ the wave frequency. The Poisson’s ratio equals 0.5 in incompressible organs such as 
the liver, and the second part of the equation equals µ, the shear modulus. Therefore, 
equation [8] can be further simplified as follows: 
 
E = 3 µ         [Equation 9] 
 
Where the Young’s modulus measured at ultrasound equals 3 times the shear modulus 
measured at MRE. This unflawed relationship only happens in the perfect elastic material 
that conserves its volume after the removal of the stressful agent. However, tissues are not 
perfectly elastic but viscoelastic (90, 92). 
The complex-valued shear modulus can also be converted into the wave number (k) with 
equation [10] (Fig. 42) (94).  
 
G* = ρ x ω2/ k2        [Equation 10] 
 
Where G* is the complex shear modulus, ρ the density of the organ, ω the circular 
frequency and k the wave number (or wave vector). The wave number is a complex 
number composed of a real part, propagation coefficient β (mm-1) and an imaginary part, 
attenuation coefficient α (mm-1).  
The propagation coefficient β is inversely related to the wavelength (λ), as described in the 
following equation: 
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β = 2 π / λ                                                                                                       [Equation 11] 
 
 
Figure 42. The wave number (k) and the Shear Modulus (G*) are complex numbers 
consisting of real and imaginary parts.  Equation adapted from [94]. 
 
 
 
This complete assessment of the viscoelastic parameters and wave-related coefficients is 
until now only reliably obtained with three-directional, three-dimensional (3D) MR 
elastography. MRE can easily be added to the standard abdominal MRI protocols and only 
adds a very small incremental time.  
MRE was found to accurately distinguish between fibrosis stages (AUROC 0.91 - 0.99) 
and with a better performance compared to transient elastography alone (Table 9) or in 
combination with the aspartate-to-platelet ratio (95 - 98). Moreover, MRE has several 
advantages compared to the ultrasound-based methods. First, an acoustic window is not 
required and it is operator independent. Second, the whole 3-dimensional displacement 
vector is assessed. Third, it enables the analysis of a larger liver volume. Fourth, the 
generation and good propagation of compressional waves allows the evaluation of obese 
patients and patients with ascites (Fig. 43). Fifth, MRE can be integrated into a complete 
clinical liver examination and the measured parameters are not affected by the prior use of 
gadoxetic acid (44, 95, 99, 100). It should also be noted that with very rapid gradient echo-
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based MRE sequences the presence of increased hepatic iron content is no longer a 
limitation for this technique (101).  
 
Table 9. Areas Under ROC Curves With 95% Confidence Intervals for MR Elastography and 
Transient Elastography 
 
 
Reproduced from [95]. 
 
 
 
 
 
 
 
Figure 43. Left: External transducer that generates the mechanical vibration. Right: coronal 
MR image showing the placement of the transducer on the right flank of the patient (arrow). 
 
 
Data regarding the influence of steatosis and inflammation on the measured MRE 
viscoelastic parameters is, nonetheless, limited and contradictory. In the two clinical 
studies by Huwart et al (95) and Yin et al (96) no independent effect was found for 
inflammation and steatosis on the measured shear modulus in patients with chronic liver 
diseases. However, in the clinical study by Chen et al (102) the shear modulus increased in 
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patients with NAFLD that presented pure inflammation but no fibrosis. In these 
aforementioned clinical studies, only one viscoelastic parameter was measured, thus 
lacking important information about the complex behavior of the shear, storage and loss 
moduli and the wave number. Until now only the work by Salameh et al (103) in animal 
models of steatosis and fibrosis started to shed a light on this matter since the authors 
found that viscosity related closely with steatosis while elasticity was particularly linked 
with inflammation and fibrosis.  
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Since magnetic resonance imaging techniques have been described in this section, a brief 
note should also be made about the hepatobiliary MR contrast agent, gadolinium 
ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA), even though it wasn’t 
used in the current work.  
 Gd-EOB-DTPA is used in routine clinical practice in many countries, including Portugal. 
This compound has a lipophilic residue attached to the DTPA that specifically targets the 
agent for uptake into the organic anion transport polypeptide (OATP1B1/3) in the 
sinusoidal plasma membrane of the hepatocyte. The contrast agent is excreted into the bile 
by the multidrug resistance protein (MRP2) (104). It is estimated that the hepatocyte 
uptake for the gadoxetic acid disodium is approximately 50% of the injected dose, which is 
ten times higher than the other available hepatospecific contrast agent (Gd-BOPTA).  With 
this contrast agent, a delayed hepatobiliary phase, usually performed 20 min after the 
injection, is added to the dynamic MR imaging, (104 - 107). Several studies used Gd-EOB-
DTPA to evaluate liver function and stage fibrosis, with simple or more complex 
pharmacokinetic analysis, and have obtained encouraging results (105-107). However, 
precaution is warranted in the analysis of these results, as many aspects have to be taken 
into account such as the lack of linear relationship between signal enhancement and the 
contrast concentration, factors that might influence the clearance of the contrast agent or 
even the known complexity of transporter proteins regulation (104).  
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3.1. Overview and Aims of the Studies  
 
3.1.1. Overview of the studies  
All the results presented in this thesis were based on 5 clinical studies and 1 
experimental animal study. Tables 10 and 11 provide the reader with a brief 
description of the aforementioned research. 
 
Table 10. Overview of the clinical studies  
 
 
 
 
 
Table 11. Overview of the experimental animal study 
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3.1.2. Aims of the Studies 
 
Chapter IV study: MR fat fraction mapping: a simple biomarker for liver steatosis 
quantification in nonalcoholic fatty liver disease patients. 
The purpose of this prospective, single-center and clinical study was to assess the 
performance, cut-off values, post-processing time, and intra- and interobserver agreement 
of a simple MR-based mapping technique to quantify liver fat in the daily clinical setting. 
 
 
Chapter V study: Fat deposition decreases diffusion parameters at MRI: a study in 
phantoms and patients with liver steatosis. 
The objective of this study was to estimate the effect of fat deposition on the MR-derived 
apparent and pure diffusion coefficients, in lipid-based phantoms and patients with pure 
liver steatosis, as proven by histopathology. 
 
Chapter VI study: The influence of liver fibrosis, inflammation and steatosis on MR 
diffusion and viscoelastic parameters: a study in patients with chronic liver disease. 
In this prospective and single-center clinical study we investigated the influence of liver 
fibrosis, inflammation and steatosis on the measured MR viscoelastic and intravoxel 
incoherent motion parameters.  
 
Chapter VII experimental study: Molecular imaging of liver fibrosis with EP-2104R: a 
feasibility study in rats. 
In this experimental and feasibility study a fibrin-targeted MR contrast agent, the EP-
2104R, was evaluated in its ability to detect moderate and severe fibrosis, induced by 
diethylnitrosamine (DEN) in rats. 
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Chapter VII clinical study 1: Accuracy and reproducibility of shearwave elastography to 
assess liver fibrosis in patients with chronic viral hepatitis and nonalcoholic fatty liver 
disease. 
The purpose of this prospective and single-center clinical study was to evaluate the 
performance of ultrasound-based shearwave elastography to detect patients with a fibrosis 
stage ≥ F2. Moreover, the interobserver reproducibility and the influence of inflammation 
and steatosis on the measured liver stiffness were assessed. 
 
Chapter VII clinical study 2: Evaluation of multifrequency MRE wavelength exponent in 
patients with liver fibrosis and inflammation:  a feasibility study. 
In this prospective and single-center clinical study the performance of the multifrequency-
derived MRE wavelength exponent was studied in patients with liver fibrosis and 
inflammation. 
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4.1. MR fat fraction mapping: a simple biomarker for liver steatosis quantification in 
nonalcoholic fatty liver disease patients 
 
Introduction 
 
Nonalcoholic fatty liver disease is being increasingly recognized as a disease associated to 
liver-related morbidity and even mortality in the western countries. Its prevalence has been 
rising in the past two decades to become the leading cause of chronic liver disease, being 
closely associated to insulin resistance and type 2 diabetes (1, 3). This chronic liver disease 
includes not only bland steatosis but also steatohepatitis, which can progress to fibrosis, 
cirrhosis and ultimately hepatocellular carcinoma (3). Although early stages of liver 
steatosis may be reversible, patients can progress to nonalcoholic steatohepatitis even 
without any proven inflammation or cell injury (108 - 111). Liver biopsy is the current 
gold standard for diagnosing nonalcoholic fatty liver disease and quantifying liver fat. 
However, its invasive nature limits the use for screening or follow-up of nonalcoholic fatty 
liver disease patients (28). Alternative noninvasive imaging methods, such as magnetic 
resonance spectroscopy and multiecho (≥ 6 echos) gradient-echo imaging with or without 
fat spectral modeling, have been used to accurately quantify liver fat (67, 112 - 115). 
However, they are time-consuming and require the use of extensive logarithmic 
calculations. Yokoo et al (112 - 113) have recently found no significant differences 
between triple echo gradient-echo imaging and the more complex methods for fat 
quantification. Therefore, the purpose of our study was to (1) assess the performance and 
specific cut-off value of a simple MR-based mapping technique for liver fat quantification 
at 1.5-T in patients at risk for nonalcoholic fatty liver disease, (2) quantify the time it can 
add to routine clinical practice abdominal protocols and (3) assess its intra- and 
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interobserver reproducibility.  
 
Materials and methods 
 
Study design and patients 
This prospective, single-center study was approved by the review board at our institution 
and written informed consent was obtained for all patients. Between May 2010 and June 
2011 a screening program was initiated at the Department of Endocrinology, using the 
following inclusion criteria: age 18 years and older, overweight with type 2 diabetes, at 
risk for nonalcoholic fatty liver disease, and absence of a clinical history of hepatitis, 
cirrhosis or hemochromatosis. A total of 32 patients were initially included in the study 
protocol which consisted of liver MR imaging at 1.5-T (Magnetom Symphony, Siemens 
Healthcare, Erlangen, Germany), using a four element surface coil, performing a triple 
echo gradient-echo T1-weighted MR imaging, from which the fat fraction mapping was 
processed, and 1H magnetic resonance spectroscopy, used as the reference standard. Six 
patients were excluded for the following reasons: 2 patients due to technical failure during 
the magnetic resonance spectroscopy acquisition, 2 had uninterpretable spectra and 2 
missed the scheduled MR imaging. The final study population consisted of 26 patients, 6 
men and 20 women, with a mean age of 47 years (range, 28 - 70 for women; 25 - 55 years 
for men). The mean body mass index (BMI) was 36.2 kg/m2 (range, 25 - 44 kg/m2 for 
women; 33 - 48 kg/m2 for men). 
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Magnetic resonance imaging 
 
1H magnetic resonance spectroscopy (MRS) 
Single-voxel liver spectroscopy was performed with a 30 mm x 30 mm x 30 mm voxel (27 
mL). Spectra were acquired with the use of point-resolved spectroscopy sequence (PRESS) 
during free breathing. Water suppression was not performed. To minimize T1 effects, 
repetition time was set at 3,000 ms. To correct for T2 effects, 5 average-spectra were 
collected at echo times 20, 30, 40, 50, 60 and 80 ms. Other parameters were receiver 
bandwith 2,000-Hz and 2,048 point spectral resolution. Automated optimization of 
gradient shimming was followed by manual adjustment of the central frequency, and 
spectra were used only if full width at half maximum water peak was 40 Hz or less. The 
total acquisition time was 3 min 6 s. A region of interest containing a tissue volume of 27 
mL was placed in one segment of the right liver at least 10 mm from the edge of the liver, 
avoiding vessels or focal lesions, by a radiologist with 5-year experience in MR abdominal 
imaging. The 1H magnetic resonance spectroscopy data was analyzed with the 
spectroscopic analysis package jMRUI (A. van den Boogaart, Catholic University, Leuven, 
Belgium).  We measured the water peak (H2O) at 4.7 ppm and the methylene peak (CH2) 
at 1.3 ppm (116). T2 relaxation for water and methylene were determined from their 
integral values, at each echo time, by using a standard least-squares fitting algorithm with 
the following equation (115): 
 
 A(t)=A0.e(-t/T2)                                                           [Equation 12] 
 
where A is the integral value at time t and A0 is the integral value at time 0. 
The peak areas of water and methylene corrected for T2 effects (A0 H2O and A0 CH2) were 
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used to calculate liver fat fraction with the following equation (115): 
 
 % FF= 100. A0 CH2/(A0 CH2+A0 H2O)          [Equation 13] 
 
We used the 5.56% value proposed by Szczepaniak et al (67), as a threshold for the upper 
normal limit of liver fat. Time required for post-processing the magnetic resonance 
spectroscopy data was registered in each patient.  
 
Fat fraction mapping (FFM) 
A T1-weighted 2D triple echo gradient-echo sequence was initially acquired with a 
repetition time/echo time 164/4.6 ms (In Phase1, IP1), 7.27 ms (Opposed Phase, OP), 9.98 
ms (In Phase2, IP2), matrix 192 x 256 pixels, 390-mm field of view (providing a pixel size 
of 2.0 x 1.5 mm), slice thickness 6 mm and 20° flip angle to correct for the T1-weighting 
effect. The acquisition time was 35 s. The final liver fat fraction mapping images were 
acquired on an automated pixel-by-pixel basis and computed in a post-processing 
workstation (Leonardo, Siemens Healthcare, Erlangen, Germany) using its basic 
mathematical functions as follows: 1) Images representing the IP signal intensity (SI) were 
corrected for T2* decay (SIIPco) using the arithmetic mean function, where SIIPco = (IP1 + 
IP2)/2; 2) OP images (SIOP) were subtracted from the previously obtained SIIPco images 
(SIIPco – SIOP); 3) The final fat fraction mapping images were obtained by dividing  the 
(SIIPco – SIOP) images by SI IPco images, and applying a scaling factor of 50%, as previously 
reported (117). A circular region of interest of 2 - 3 cm2 was manually placed by a 
radiologist blinded to spectroscopy results at the right liver lobe, matching the anatomical 
location of the spectroscopic region of interest and avoiding vessels or focal lesions. The 
region of interest drawn in the liver mapping provided an immediate percentage result of 
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the fat content in that area (Figs. 44, 45). A similar volume-matched region of interest was 
placed in the spleen, to serve as internal reference for technical consistency. All FFM were 
repeated 1 week later to assess intraobserver reproducibility by a radiologist with 5-year 
experience in MR abdominal imaging. Ten cases were randomly selected to assess 
interobserver reproducibility, which was performed by one radiologist with 2-year 
experience in MR abdominal imaging. The latter was previously taught to post-process the 
IP/OP images in order to obtain the fat fraction mapping in half an hour Time required for 
post-processing the FFM was registered for each patient.  
 
 
 
Figure 44. Left: 1H magnetic resonance spectra. Liver fat content was 5.7 %. Right: Liver fat fraction 
mapping of a 67-year old patient with type 2 diabetes. Region of interest (1) positioned in the liver 
directly provides the respective fat fraction value of 6.7 %. Liver signal is only slightly more intense 
compared to the spleen (internal reference standard). 
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Figure 45. Left: 1H magnetic resonance spectra. Liver fat content was 26.7 %. Right: Liver fat fraction 
mapping of a 40-year old patient with type 2 diabetes and severe steatosis. Liver fat is clearly visible on 
the mapping, as the liver is very hyperintense compared to the spleen. Measurements in the liver (1) and 
spleen (2) provide fat fraction within regions of interest (25.5 % and 1.3 %, respectively). 
 
 
Statistical Analysis 
 
In this prospective study an a priori power analysis was performed in order to obtain a 
significance of 0.05 and a power of at least 80%. Previous reports in the literature for the 
prevalence of liver steatosis and mean liver fat content in a similar population were used 
for that purpose (114, 118). A minimum number of 21 patients had to be included in our 
study. 
 The correlation between the fat fraction mapping measurements and magnetic resonance 
spectroscopy was assessed using the non-parametric Spearman rank correlation coefficient 
(r). The evaluation of bias was done using the 95% limit-of-agreement method developed 
by Bland and Altman (119), in which the difference between fat content measured by two 
methods is plotted against their mean. The performance of the fat fraction mapping was 
assessed by plotting the true positive rate in function of the false positive rate for different 
cut-off points, which allowed calculating the area under the curve of a receiver operating  
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characteristic curve and determining the cut-off value for the technique. The difference in 
acquisition and post-processing times between both methods was assessed using the non-
parametric Wilcoxon test. Intra- and interobserver reproducibility was calculated using 
intraclass correlation coefficients. A P value ≤ 0.05 was considered statistically significant. 
Statistical analysis was performed with the MedCalc software (MedCalc, Mariakerke, 
Belgium). 
 
Results 
 
In this patient cohort a mean fat percentage of 11.7% (range, 2 - 35.4%) was obtained 
using the FFM technique corresponding to 9.8% (range, 0.8 - 30%) using MRS (Table 12). 
A strong correlation was found between both methods (r = 0.89, P < 0.0001). On the 
Bland-Altman plot 25 of the 26 fat measurements were within ± 4.2% of the mean 
difference of both methods (2%) (Fig. 46). Using the reference threshold proposed by 
Szczepaniak et al (67) for MRS, we found that a cut-off value of 6.9% for FFM provided 
an accurate diagnosis of fat content with 93% sensitivity and 100% specificity. The area 
under the curve for fat fraction mapping was 0.99. The spleen was used as our internal 
reference and all spleen measurements had a fat content ≤ 1.5% (Fig. 45). Median post-
processing and reading time was 5 minutes (range, 5 - 15 min) for FFM and 35 minutes 
(range, 30 - 50 min) for MRS (P < 0.0001). Intraclass correlation coefficients for intra- and 
interobserver agreement were 0.98 (95% CI, 0.96 - 0.99) and 0.99 (95% CI, 0.97 - 0.99), 
respectively. 
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Table 12. Fat fraction measurements with FFM and MRS in the 26 patients 
FFM (%) 
4.8 
2.8 
2.6 
27.4 
4.5 
35.4 
15.7 
2.0 
6.7 
12.0 
15.9 
10.8 
3.0 
20.8 
25.5 
12.6 
6.9 
2.5 
5.3 
11.4 
16.8 
6.7 
2.2 
6.8 
31.7 
12.0 
MRS (%) 
1.2 
0.8 
0.8 
28.6 
1.2 
30 
14.2 
1.0 
5.7 
7.0 
15 
7.3 
1.0 
21.7 
26.7 
10.8 
3.1 
1.0 
1.3 
10.3 
20.5 
1.6 
0.8 
4.4 
29.3 
11.0 
 
 
 
Figure 46. Bland-Altman plot representing the difference between liver fat fraction (%) estimated with 
magnetic resonance spectroscopy and mapping (measured by observer 1 at one time point) plotted 
against their means. Only one fat fraction measurement wasn’t within the ± 1.96 SD  (4.2 %) of the mean 
for both methods, but all fat fraction measurements stayed within the upper maximum and lower minimum 
95 % limit of agreement.  SD = Standard Deviation. 
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Discussion 
 
In this prospective, single-center study we have assess the performance, post-processing 
time, intra- and interobserver agreement of an MR-based mapping for liver fat 
quantification using a triple-echo gradient-echo sequence for T2* correction. Our results 
show that this mapping can accurately provide liver fat quantification within a short post-
processing time with excellent intra- and interobserver agreement. The cut-off value of 
6.9% for the mapping method was found to have the best sensitivity and specificity to 
diagnose patients with and without liver fat deposition. Histological assessment of liver 
biopsy is considered the reference standard for the diagnosis of steatosis but its use for 
screening or follow-up studies remains impractical due to its invasive nature. Moreover, it 
is subjected to important sampling errors since liver steatosis is a heterogeneous process 
often associated with spared areas that may be related, among other reasons, to vascular 
abnormalities (120). The noninvasive quantification of liver fat has been made possible by 
the use of magnetic resonance imaging with either 1H magnetic resonance spectroscopy or 
multiecho gradient-echo sequences. However, spectroscopy has limited spatial coverage 
and requires substantial expertise for its implementation and analysis, and the multiecho 
sequences (≥ 6 echos) require the use of equations with increasing complexity and 
additional analysis software to measure fat content (25, 53, 112). Recently good agreement 
of fat fraction measurements between MRS and triple echo gradient-echo imaging over a 
wide range of fat content was reported (112).  The FFM technique used in our study also 
showed very good correlation with MRS, although the correlation coefficient was lower 
than previous reports (≈ 0.98) (119). This may probably be explained by two factors: first, 
due to technical limitations at 1.5-T we assumed a simplified fat spectrum consisting of a 
single methylene peak at 1.3 ppm (116), while gradient-echo magnetic resonance imaging 
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includes signals from all fat peaks. Secondly, T2* effect was corrected assuming a linear 
T2* decay between the two IP echoes, as previously observed by Guiu et al (117). 
However, to insure that no bias from T2* decay influenced our measurements we used the 
first two closely spaced in-phase echo times to obtain the in-phase corrected signal. These 
two in-phase echo times have superior signal-to-noise ratio and are less influenced by fat-
fat interference. We are aware that the FFM technique does not solve the problem of fat-
water ambiguity since subcutaneous fat will show values of 8 - 12%, when the real fat 
fraction is obtained subtracting this value from 100%. However, liver fat fractions higher 
than 50% are very uncommon in the liver parenchyma (67, 112, 114, 118). The highest fat 
fraction measured in the present study was 35.4%. When performing visual assessment of 
the map, liver fat is hyperintense compared to the spleen, our internal reference. The spleen 
does not contain visible fat on MRI except in cases of lipid storage disorders and after 
administration of intravenous fat emulsions (117, 121). Since splenic measurements 
obtained for all patients were consistently ≤ 1.5%, it allowed us to conclude about the good 
reproducibility of the technique.  
The Bland-Altman plot showed that the fat fraction measurements for all patients, except 
one, were within ± 4.2% of the mean difference of both methods. This is a fairly 
reasonable value considering that quantification of liver fat by visual assessment on 
pathological specimens has broader grading limits (4). The median time spent for 
acquisition and post-processing of 1H MRS in our study was ≈ 38 min, which can at least 
be partially explained by the lack of fully automated spectral analysis software. However, 
the mean time spent to produce and analyze FFM was only 5 min 35 s, which makes the 
technique a realistic choice to incorporate in a busy clinical setting. Compared to previous 
studies that only assessed the agreement of the mapping technique with respect to an 
imaging gold standard (114, 117), we have determined its cut-off value and intra- and 
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interobserver reproducibility.  Using 6.9% as a cut-off value can accurately distinguish 
patients with and without liver steatosis. Furthermore, in our work excellent intra- and 
interobserver reproducibility were observed and we believe that this is an additional reason 
to apply FFM as a potential biomarker for liver steatosis quantification.  
The clinical relevance of FFM must be considered especially in the setting of longitudinal 
population-based epidemiologic studies, since recent studies have reported a 5% 
prevalence of fatty liver in the general pediatric population, 38% in obese children and 48 
% in children having type 2 diabetes (122). 
Our study has limitations: first, steatosis quantification was not confirmed by histology 
since performing liver biopsy in asymptomatic patients is not ethically justified, and may 
be under representative since only 1/50000 of the organ is actually analyzed (4); second, 
the absence of liver iron overload was not histologically verified but it must be stressed 
that the present series was composed of patients only at risk for nonalcoholic fatty liver 
disease, without clinical or biological evidence of iron overload; third, we were not able to 
test the longitudinal reproducibility of FFM since each patient was submitted to a single 
MR session for each quantification technique.  
In conclusion, FFM is a simple and accurate technique for liver steatosis quantification. 
Since it can be performed in a short time frame it can potentially be included in routine 
liver studies dealing with this clinical problem, especially in the setting of large 
longitudinal population-based epidemiologic studies. 
 
 
 
 
 
 100
 
 
 
 
 
 
 
 
 
 
 
 
 
Fat Deposition Decreases Diffusion 
Parameters at MRI: a Study in Phantoms 
and Patients with    Liver Steatosis 
 
 
 
                                                 
 
                                                 Chapter V 
101  
5.1.Fat deposition decreases diffusion parameters at MRI: a study in phantoms and 
patients with liver steatosis 
 
Introduction 
Chronic liver diseases are frequent causes of morbidity and mortality in the Western 
countries. In a recent screening study performed in a general population older than 45 
years, liver fibrosis related to unsuspected chronic liver disease was detected in 7.5% of 
the subjects and cirrhosis in about 1% (123). The most frequent causes of chronic liver 
diseases encountered were nonalcoholic fatty liver disease (NAFLD), alcoholic liver 
disease and viral hepatitis C and B (123). Among these, nonalcoholic fatty liver disease is 
a major healthcare problem since excessive liver fat is detected in one third of the United 
States adult population (67, 122). 
Recently, various imaging methods, including diffusion-weighted magnetic resonance 
imaging, have emerged as potential biomarkers for chronic liver disease (67, 97). Prior 
studies have shown that chronic liver diseases are associated with a decrease of the 
diffusion coefficients. This has been related to progressive fibrosis, inflammation and 
decreased perfusion  (81, 82, 85, 87, 124). Liver steatosis is also frequently observed in 
patients with liver fibrosis, especially in patients with nonalcoholic and alcoholic liver 
diseases and viral hepatitis C and B (53, 108). 
However, only few and conflicting data are available regarding the influence of liver 
steatosis on the diffusion parameters. In most reported studies liver steatosis is considered 
not to restrict diffusion (85, 115, 125). Two recent studies performed in patients and rats 
suggested a relationship between steatosis and diffusion (126, 127). However, because no 
liver biopsies were obtained in the patient study, the effect of confounding factors such as 
fibrosis and inflammation on the diffusion measurements could not be assessed. In the
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animal study, biopsies were obtained, but a multivariate analysis of the influence of 
steatosis, inflammation and fibrosis on the diffusion measurements was not performed. 
Therefore, the purpose of our study was to assess the effect of fat deposition on the MRI 
diffusion coefficients, in lipid emulsion-based phantoms and in patients with normal liver 
and with isolated liver steatosis, without any other confounding factors, as confirmed by 
histopathology.  
 
Material and methods 
 
Lipid emulsion-based phantom study 
The phantoms consisted of 50 mL tubes containing a constant amount of 5 mL of gelatin, 
used as a solidification agent.  To obtain the various fat fractions in the phantoms, we 
progressively increased the added amount of a lipid emulsion of refined olive oil (16%) 
and soybean oil (4%) (ClinOleic 20%, Baxter, Maurepas, France) in each tube and 
decreased the added amount of water in parallel. The final fractions of fat in the phantoms 
ranged from 0 to 18% (0%, 3%, 5%, 7%, 9%, 12%, 14%, 16%, 18%). Fat droplets inside 
the phantoms had a mean diameter of 0.6 microns, which is similar to that of fat droplets 
within the hepatocyte cytoplasm (about 1 micron) (128, 129).   
The phantoms were imaged using 1.5T MR (Intera, Philips Medical Systems, Best, The 
Netherlands) with a four-element surface coil. Diffusion-weighted magnetic resonance 
imaging was performed without and with a fat suppression scheme (Spectral Presaturation 
with Inversion Recovery), using a single-shot echo-planar acquisition and the following 
parameters:  repetition time/echo time 305/57 ms, matrix 80 x 80 pixels, 250-mm field of 
view, 3 transverse slices, slice thickness 4 mm, 11 b values (0, 10, 20, 30, 40, 50, 75, 100, 
150, 300 and 500 s/mm2), 20 averages and 3 directions. The acquisition time was 3 
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minutes 30 seconds.  
 
Patient study 
This retrospective clinical study was approved by the review board at our institution and 
informed consent was waived. Patients who underwent magnetic resonance imaging for 
the assessment of a liver tumour, between June 2010 and March 2011, were identified for 
this study. Inclusion criteria were: age 18 years and older; liver MRI with a multi-b 
diffusion-weighted sequence; histopathological assessment of the tumour and non-
tumourous liver parenchyma performed by liver biopsy or after surgical resection. Ninety-
seven patients were identified based on the inclusion criteria.  
The diffusion-weighted images in the patients were obtained using the same 1.5T MRI 
system and surface coil described above for the phantom study. The multi-b single-shot 
echo-planar diffusion-weighted acquisition had the following parameters:  repetition 
time/echo time 305/57 ms, matrix 80 x 80 pixels, 320-mm field of view, 3 transverse 
slices, slice thickness 4 mm, 11 b values (0, 10, 20, 30, 40, 50, 75, 100, 150, 300 and 500 
s/mm2), 20 averages and 3 directions. Image acquisition was obtained with fat suppression 
(Spectral Presaturation with Inversion Recovery) and free breathing. The acquisition time 
was 3 minutes 30 seconds.  
Exclusion criteria were as follows: motion artefact on the diffusion-weighted images 
precluding the analysis of the diffusion parameters (7 patients); liver inflammation, 
fibrosis, cirrhosis or iron overload at histopathological evaluation (71 patients). The final 
study population consisted of 19 patients, 12 women and 7 men, with a mean age of 50.7 
years (range: 24 - 72 years for women; 37 - 74 years for men). The median interval 
between magnetic resonance imaging and biopsy (n = 16) or surgical resection (n = 3) was 
14.5 days (range: 0 - 90 days).  
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For the patients included in the study, the non-tumourous liver biopsies were 
retrospectively reviewed by an experienced hepatobiliary pathologist who was unaware of 
imaging results. This evaluation confirmed the absence of steatosis, inflammation, fibrosis 
and iron (n = 14, normal liver) or the presence of isolated liver steatosis (n = 5), and 
grading was performed according to the Brunt classification (4): three patients had grade 1 
steatosis (number of hepatocytes containing fat: 5 – 33%), one grade 2 (33 – 66 %) and 
one grade 3 (> 66%).  
 
Image interpretation 
Regions of interest were placed on the diffusion-weighted images, by one of the authors 
with 5-year experience in MRI, blinded to the results of histopathology. The regions of 
interest were placed within the center of each test phantom to avoid edge artifacts and in 
the right liver avoiding large vessels and focal liver lesions.  The absence of a liver lesion 
or large vessel in the region of interest was confirmed by visually comparing the region of 
interest positioned on the diffusion-weighted, T1 and T2-weighted images. The mean area 
for the regions of interest was 4.3 ± 0.5 cm2 in the lipid emulsion-based phantoms and 18 ± 
6.8 cm2 in patients.  
The apparent diffusion coefficient was measured using a monoexponential model (130) 
with the following equation:  
 
Sb/S0 = exp (-b ADC)         [Equation 14] 
 
where ADC (10-3 mm2/s)  is the apparent diffusion coefficient, Sb the signal intensity for 
each b value and S0 the signal intensity at b0. 
The other diffusion coefficients were measured using a bi-exponential fit (130) with the 
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following equation:  
 
Sb/S0 = (1-f) exp (-b D) + f exp (-b (D + D*))         [Equation 15]  
 
where, f (%) is the fraction of diffusion linked to microcirculation, D (10-3 mm2/s) the true 
diffusion coefficient,  and D* (10-3 mm2/s) the perfusion-related diffusion coefficient.  
The algorithms were implemented with purpose built software running under the ROOT 
environment (ROOT 5.22, CERN, Geneva, Switzerland). The reproducibility of the 
diffusion parameters measurements has been reported previously (131). 
 
Statistical analysis 
 
The results are reported as mean ± standard deviation. The correlation between the fat 
fraction and the diffusion coefficients for the lipid emulsion-based phantoms was 
calculated with Spearman correlation coefficients (r). The diffusion parameters of the 
patients with and without isolated liver steatosis were compared with the Mann-Whitney U 
test after Bonferroni correction. P ≤ 0.01 was considered to indicate a statistically 
significant difference. Statistical analysis was performed with the MedCalc software 
(MedCalc, Mariakerke, Belgium). 
 
Results 
 
The results of the diffusion parameters measurements in the phantoms are given in table 
13.  The apparent and pure diffusion coefficients decreased from 2 and 2.1 x 10-3 mm2/s, 
for a fat fraction of 0%, to 1.42 and 1.49 x 10-3 mm2/s, for a fat fraction of 18%, with fat 
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suppression, and from 2.04 and 2.1 x 10-3 mm2/s, for a fat fraction of 0%, to 0.89 and 0.88 
x 10-3 mm2/s, for a fat fraction of 18%, without fat suppression, respectively. A strong 
inverse correlation was found between fat fraction and apparent and pure diffusion 
coefficients, either with fat suppression (r = - 0.98, P < 0.0001; r  = - 0.97, P < 0.0001, 
respectively) or without fat suppression (r = - 0.99, P < 0.0001; r  = - 0.99, P < 0.0001, 
respectively). The measured perfusion fractions (1.8 ± 1% and 1 ± 0.8% with and without 
fat suppression, respectively) and the perfusion-related diffusion coefficients (6.7 ± 3.5 x 
10-3 mm2/s and 3.6 ± 2.4 x 10-3 mm2/s) were almost zero. 
In patients with normal liver, the pure diffusion coefficient was significantly higher than in 
patients with isolated liver steatosis (1.18 ± 0.09 x 10-3 mm2/s versus 0.96 ± 0.16 x 10-3 
mm2/s, P = 0.005) (Figs. 47 - 49). The apparent diffusion coefficient, perfusion-related 
diffusion coefficient and perfusion fraction did not differ significantly between patients 
without and with isolated liver steatosis, but there was a small decrease trend of the 
apparent diffusion coefficient in patients with liver steatosis (apparent diffusion 
coefficient: 1.41 ± 0.14 x 10-3 mm2/s versus 1.26 ± 0.25 x 10-3 mm2/s, P = 0.298; 
perfusion-related diffusion coefficient: 99.9 ± 2.18 x 10-3 mm2/s versus 99.6 ± 3.79 x 10-3 
mm2/s, P = 0.754; perfusion fraction: 21 ± 2% versus 23 ± 4%, P = 0.431, respectively). 
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 Table 13. Apparent (ADC x 10-3 mm2/s) and pure (D x 10-3 mm2/s) diffusion coefficients, measured without and with fat suppression, in lipid emulsion-based 
phantoms, according to the fat fraction
Fat fraction (%)    0              3      5 7 9 12 14  16     18 
                        r                    P 
  
         
ADC without fat suppression 
 
2.04        1.81  1.69 1.57 1.39 1.15 1.10 1.09 0.89 - 0.99 < 0.0001 
ADC with fat suppression 
 
2.00 1.94 1.81 1.74 1.69 1.68 1.61 1.54 1.42 - 0.98 < 0.0001 
D without fat suppression 
 
2.1 1.84 1.74 1.60 1.42 1.17 1.11 1.09 0.88 - 0.99 < 0.0001 
            
D with fat suppression 
 
2.1 2.02 1.90 1.82 1.76 1.75 1.68 1.62 1.49 - 0.97 < 0.0001 
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         a                 b 
Figure 47. Box and whisker plots showing the apparent (a) and pure (b) diffusion coefficients (x 10-3 
mm2/s) according to the presence or absence of liver steatosis. Central box represents the values from 
the first to third quartiles and the middle line represents the median. The vertical line extends from the 
minimum to the maximum value within 1.5 times the interquartile range. Outliers are represented as 
individual points. No significant difference of apparent diffusion coefficient is observed between the two 
groups (a). The pure diffusion coefficient (b) is significantly lower in the steatotic group (P = 0.005). 
 
 
 
Figure 48. Left: Diffusion-weighted image at b = 10 s/mm2. Right: the same image with a 
superposed parametric color map of the pure diffusion coefficient, with a scale in mm2/s, in 68-year 
old woman without liver steatosis. The measured pure diffusion coefficient was 1.3 mm2/s. The region 
of interest was placed in the right lobe, away from regions with apparent increase of diffusion. This 
apparent increase of diffusion in the left lobe may be explained by the flow in the large hepatic veins and 
transmitted cardiac motion. 
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Figure 49. Left: Diffusion-weighted image at b = 10 s/mm2.  Right: the same image with a 
superposed parametric color map of the pure diffusion coefficient, with a scale in mm2/s, in 52-year 
old woman with liver steatosis. The measured pure diffusion coefficient (0.82 mm2/s) was lower than 
that observed in a patient with normal liver. 
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Discussion 
 
In this study performed in lipid emulsion-based phantoms and patients with and without 
isolated liver steatosis, we have observed that the presence of fat droplets decreases the 
apparent and pure diffusion coefficients. In tissues containing both water and fat, it has 
been reported that slow diffusion may be explained by a restriction of water diffusion due 
to abundant lipids and by diffusion of mobile lipids, which is a slow phenomenon, 
occurring at a rate that is 100 times slower than water diffusion (132, 133). The respective 
influence of restricted water diffusion and slow lipid diffusion on the decrease of the 
diffusion parameters in steatosis is unknown. This influence will depend on the use of fat 
suppression. Without fat suppression, both restricted water diffusion and slow lipid 
diffusion may be observed, whereas with perfect fat suppression, only restricted water 
diffusion should be observed. Our findings in phantoms agree with these concepts, as the 
diffusion parameters measurements were higher with fat suppression than without. In 
vivo, perfect lipid signal suppression cannot be obtained, as multiple technical and 
biological reasons are at stake, including the fact that two of the fat spectrum peaks 
(olefinic acid at 5.3 ppm and glycerol at 4.2 ppm) have frequencies very close to that of 
the water peak (at 4.7 ppm) (116).  These lipid peaks, representing 8 - 10% of the total fat 
spectrum, cannot be suppressed at clinical field strengths, without also suppressing the 
water peak. Residual fat signal on fat suppressed diffusion-weighted images may decrease 
the measured diffusion parameters in two ways. First, slow lipid diffusion may be 
observed in these fat areas. Second, residual fat signal on high b-value diffusion-weighted 
images, may artefactually decrease the measured diffusion parameters (134, 135). 
Regardless of the cause, our results show that isolated liver steatosis decreases the 
diffusion parameters measurements.  
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We observed similar results in liver steatosis and in phantoms closely mimicking this 
clinical condition. In contrast to the lipid phantom models previously described in the 
literature, containing unmixed volumes of water and mineral oil in a container, imaged 
with an oblique imaging plane through the boundaries of both chemical environments to 
obtain different concentrations of water and fat (136, 137), our phantoms consisted of lipid 
emulsions, with lipid droplets similar in size and concentration to the lipid inclusions in 
hepatocytes. Indeed, as mentioned in material and methods, the size of the lipid droplets in 
our phantoms (0.6 microns) was close to that of intracellular fat droplets in liver steatosis 
(about 1 micron). Moreover, the fat percentages in the phantoms (0 – 18%) covered a wide 
range of steatosis severity. It has previously been shown that the percentage of fat-
containing hepatocytes is about 2.75 higher than the percentage of fat on a volume basis 
(138). This means that a fat percentage of 18% in the phantoms, relates to almost 50% of 
fat containing hepatocytes, i.e. moderate to severe steatosis according to the Brunt 
classification (4). 
With respect to the clinical study and to the best of our knowledge, this is the first biopsy-
proven study that reports the definite influence of isolated liver steatosis, with no other 
pathological confounding factors, on the diffusion parameters. Until now, limited and 
conflicting results have been published regarding the influence of steatosis on the 
diffusion parameters. In most studies, no significant influence was observed (85, 115, 
125). Recently, an inverse correlation between the apparent diffusion coefficient and 
hepatic fat fraction was reported in ex-vivo rat livers by Anderson SW et al. (126) and in 
patients by Poyraz AK et al. (127). However, these two studies are limited by the absence 
of information about the specific influence of steatosis, inflammation and fibrosis on the 
apparent diffusion coefficients measurements. Namely, in the retrospective clinical study 
by Poyraz AK et al. (127), liver biopsy was not obtained. In the ex-vivo study by 
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Anderson SW et al. (126), histopathology was available, but a multivariate analysis of the 
influence of steatosis, inflammation and fibrosis on the diffusion measurements was not 
performed.  
Moreover, except for the study of Lee JT et al. (125), only the apparent diffusion 
coefficient was measured in these previous works. The apparent diffusion coefficient, a 
compound parameter that includes influences from pure molecular diffusion and 
perfusion-related diffusion, may be less sensitive than the individual diffusion parameters 
to changes induced by steatosis or fibrosis, as shown in our study and that of Luciani et al. 
(82). In nonalcoholic fatty liver disease, liver perfusion is decreased because of reduced 
sinusoidal volume (139). However, we did not observe a decrease of the perfusion-related 
diffusion parameters in patients with liver steatosis. Several factors may explain this 
apparent discrepancy such as, the small number of patients with isolated liver steatosis in 
our study, and the known difficulty of obtaining reliable results for the perfusion-related 
diffusion parameters (140). Moreover, decreased perfusion has mainly been observed in 
steatohepatitis rather than in isolated steatosis, because sinusoidal compression and 
distortion in steatohepatitis are caused not only by fat deposits within hepatocytes, but also 
by hepatocyte hydropic ballooning, fibrosis of the space of Disse and leukocyte adhesion 
to the sinusoidal endothelium (139, 141).  
Diffusion-weighted magnetic resonance imaging is not used to quantify liver fat, since 
other methods, such as proton spectroscopy and multi-echo gradient-echo imaging, are 
accurate for that purpose (67, 112). However, our results show that liver steatosis may 
decrease the measured diffusion parameters in chronic liver diseases. In addition to liver 
inflammation and decreased liver perfusion, which have previously been shown to 
decrease the diffusion parameters (81, 85, 87, 142), liver steatosis is hence a confounding 
factor when trying to stage liver fibrosis at diffusion-weighted MRI. Concomitant liver 
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steatosis and fibrosis are often observed in chronic liver diseases, not only in nonalcoholic 
and alcoholic steatohepatitis, but also in chronic viral hepatitis (143).  
In our study, the decrease of diffusion parameters in patients with liver steatosis concerned 
the true diffusion coefficient, but not the apparent diffusion coefficient, calculated with a 
monoexponential approach using 11 b values, ranging from 0 to 500 s/mm2. It has been 
recently recommended to calculate the apparent diffusion coefficient with a 
monoexponential approach using at least 2 b values > 100 s/mm2 to avoid the perfusion 
effect on the measured value (75).  In this case, the apparent diffusion coefficient equals 
the true diffusion coefficient and liver steatosis also decreases the apparent diffusion 
coefficient calculated with this method. 
Our study has limitations. Firstly, the number of included patients was small, because we 
excluded all patients with combined fat infiltration, iron overload, fibrosis and/or 
inflammation. The small cohort of patients with isolated liver steatosis might explain why 
we have not found a significant difference in the apparent diffusion coefficient between 
the two subgroups of patients, since this composite parameter is less sensitive than the 
pure diffusion coefficient. Because of the small number of patients, we did not correlate 
the diffusion parameters with liver fat fractions. However, our phantom study suggests 
that increasing fat fraction correlates with decreasing diffusion.  A larger prospective 
study in patients with isolated liver steatosis is needed to confirm these findings.   
Secondly, we acquired free-breathing echo-planar diffusion-weighted imaging and 
physiological motion is always a concern when studying the microscopic displacement of 
protons. However, good reproducibility of the diffusion parameters was reported with free 
breathing or navigator-echo triggered sequences (75, 83). 
In conclusion, our results show that the presence of fat droplets decreases the diffusion 
parameters and suggests that steatosis may have confounding effects when measuring the 
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diffusion parameters at MRI. 
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6.1. The influence of liver fibrosis, inflammation and steatosis on the MR diffusion 
and viscoelastic parameters: a prospective study in patients with chronic liver disease 
 
Introduction 
Chronic liver diseases such as viral hepatitis and nonalcoholic fatty liver disease, are a 
major cause of morbidity and mortality worldwide. Their prevalence has been rising in the 
last decade mostly due to nonalcoholic fatty liver disease that increases along with 
metabolic conditions and obesity. Furthermore, the latter can also be associated with other 
causes of chronic liver diseases in the same patient (1, 144). Liver biopsy is commonly 
used as the reference standard to evaluate fibrosis and the associated inflammation and 
steatosis, but it has inherent risks, poor reproducibility and a low performance for 
intermediary stages of fibrosis (145). Moreover, from a patient’s perspective the prospect 
of undergoing repeated liver biopsies for follow-up is daunting and highly inconvenient.  
Several noninvasive imaging methods such as ultrasound-based transient elastography, 
magnetic resonance elastography and diffusion-weighted imaging are used to stage 
fibrosis, and assess inflammation and steatosis (47, 48, 81, 82, 85, 95 - 97, 102, 103, 146, 
147). However, there is still a significant debate and conflicting data regarding the 
influence of the necroinflammatory activity and steatosis on the measured viscoelastic and 
diffusion parameters in patients with liver fibrosis. In three previous studies no 
independent effect was found for inflammation and steatosis on the measured liver 
stiffness and apparent diffusion coefficient, in patients with chronic liver disease (85, 95, 
96).  However, other authors reported that the presence of edema and inflammation, in 
acute hepatitis, increases liver stiffness and restricts diffusion (47, 48, 81).  The same 
effect was found on viscoelastic and diffusion parameters for cholestasis and steatosis (23, 
49, 146 - 149). Therefore, the purpose of our study is to assess the independent influence 
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of liver fibrosis, inflammation and steatosis on the measured MR diffusion and 
viscoelastic parameters. To the best of our knowledge this is the first study to evaluate this 
effect on both MR-derived parameters in the same cohort of patients. 
 
Material and methods 
 
Patients and study protocol 
The review board at our institution approved this single-center and prospective clinical 
study and informed consent was obtained for all patients. From November 2010 through 
October 2012, all consecutive patients 18 years or older, seen at the department of 
hepatology with untreated viral hepatitis and nonalcoholic fatty liver disease and 
scheduled for liver biopsy were enrolled in this study. A total of 82 patients were initially 
included in the study protocol which consisted of liver MR imaging at 1.5-T (Intera, 
Philips Medical Systems, Best, The Netherlands), using a four element surface coil, and 
performing intravoxel incoherent motion diffusion-weighted imaging and monofrequency 
magnetic resonance elastography. Fourteen patients were afterwards excluded for the 
following reasons: in 2 patients a metallic implant contraindicated the study; in 2 patients 
MR imaging was stopped because of claustrophobia; in 9 patients the presence of imaging 
artefacts precluded the analysis of the MR parameters and 1 patient was pregnant at the 
time of the scheduled MR imaging. The final study population consisted of 68 patients, 21 
women and 47 men, with a mean age of 41 years for women (range: 29 - 68 years) and 47 
years for men (range: 22 - 71 years). Thirty-nine patients had viral hepatitis C, 20 had 
viral hepatitis B and 9 had nonalcoholic fatty liver disease. An expert hepatobiliary 
pathologist who was unaware of imaging results performed the histopathologic analysis of 
all liver specimens. Fibrosis and inflammation were documented according to the 
 118
METAVIR or NAS scoring systems (27, 150, 151) and steatosis was graded according to 
the Brunt classification (4) as explained in Chapter II, sections 2.2.1. and 2.2.2.. The mean 
interval between biopsy and MR imaging was 24 days (range: 0 - 60 days).  
 
MR Imaging and post-processing analysis 
 
Diffusion-weighted imaging: 
Multi-b single-shot echo-planar diffusion-weighted imaging was acquired with a 
previously published protocol (152). Briefly, the following parameters were used: 
repetition time/echo time 305/57 ms, 320-mm field of view, matrix 80 × 80 pixels, 4 mm3 
isotropic voxels, 3 transverse slices, slice thickness 4 mm, 11 b values (0, 10, 20, 30, 40, 
50, 75, 100, 150, 300 and 500 s/mm2), 20 averages and 3 directions. Image acquisition 
was obtained with fat suppression (Spectral Presaturation with Inversion Recovery) and 
free breathing. The acquisition time was 3 min 28 s. 
Regions of interest were placed in the liver on the diffusion-weighted images avoiding 
large vessels and focal liver lesions (which was confirmed by visually comparing the 
region of interest positioned on the diffusion, T1 and T2-weighted images), by one of the 
authors with 7-year experience in MR imaging, blinded to the results of the 
histopathologic analysis. The ROIs were copied on the DW images, and ROI location was 
checked over all b images. The ROIs were then copied on the DW parametric maps, and 
mean parameter values were obtained in each ROI. Mean area for the regions of interest 
was 18 ± 6.8 cm2. The signal acquired from all the b values was used to generate the maps 
on a pixel-by-pixel basis for the intravoxel incoherent motion diffusion-weighted imaging 
parameters, using the ROOT environment (ROOT 5.22, CERN, Geneva, Switzerland). 
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All the parameters were measured by applying a segmented bi-exponential fit (130) with 
the following equation:  
 
Sb/S0 = (1-f) exp (-b D) + f exp (-b (D + D*))         [Equation 16]  
 
where Sb is the signal intensity for each b value, S0 the signal intensity at b0, f (%) the 
fraction of diffusion linked to microcirculation, D (10-3 mm2/sec) the pure diffusion 
coefficient,  and D* (10-3 mm2/sec) the perfusion-related diffusion coefficient. The 
reproducibility of the parameters measurements has been reported previously (131). 
 
Magnetic resonance elastography 
For MR elastography, harmonic mechanical waves were produced at 50 Hz by an electro-
mechanical transducer placed near the liver on the right flank of the patient in supine 
position (Fig. 42) (95, 154 - 155). Synchronous motion-encoding bipolar gradients were 
added to a spin-echo sequence to encode the three directional components of the motion in 
the phase of the MR signal. The following sequence parameters were used: repetition 
time/echo time 560/40 ms, echoplanar readout with factor 3, matrix 80 × 80 pixels, 320-
mm field of view, 7 transverse slices, slice thickness 4 mm and phase sampling of 4 points 
per vibration period.  Nulling of fat signal was performed with spectral inversion recovery. 
The acquisition time was 19 s per direction. The consistency between breath holds was 
checked visually during data processing by assessing that the liver was at the same 
location on the consecutive images. Nine patients were excluded based on this visual 
assessment. The spatial resolution (4 mm)3 was chosen as a compromise between signal to 
noise ratio, acquisition time and spatial sampling of the wave. The complex-valued shear 
modulus was calculated from the phase images scaled to displacement values by first 
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suppressing the compressional components of the waves through application of the curl 
operator. Displacement values were then used to invert the local time-harmonic wave 
equation under physical constraints of local mechanical isotropy and incompressibility, as 
previously described (156, 157). Three-dimensional maps for the complex-valued shear 
modulus (G*, kPa), storage modulus (G', kPa) and loss modulus (G'', kPa) were analyzed. 
Regions of interest were positioned in the liver on the viscoelastic maps matching the 
previous regions of interest in the DW parametric maps, by one of the authors with 6-year 
experience in MR imaging blinded to the results of the histopathologic analysis.  
 
Statistical analysis 
 
In this prospective study an a priori power analysis was performed and a minimum 
number of 45 patients had to be included to obtain a significance level of 0.05 and a power 
of 95% (95, 147). The univariate correlations between fibrosis, inflammation and steatosis 
on one hand, and the diffusion and viscoelastic parameters on the other hand were 
assessed with Spearman rank correlation coefficients (r) (158). In addition, fibrosis, 
inflammation and steatosis were introduced as independent variables in a stepwise 
multivariate regression model (the significant variables are entered sequentially, checked 
and possibly removed if non-significant), to assess their independent effect on the 
diffusion and viscoelastic parameters (159). With this model multivariate regression 
correlations (RC) were calculated. 
P ≤ 0.05 was considered to indicate a statistically significant difference. Statistical 
analysis was performed with the MedCalc software (MedCalc, Mariakerke, Belgium). 
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Results 
In the 68 patients, the histopathologic analysis revealed the following distribution: 
 fibrosis: F0 (n = 12; 18%), F1 (n = 27; 40%), F2 (n = 14; 20%), F3 (n = 9; 13%), F4 (n = 
6; 9%);  inflammation: A0 (n = 14; 20%), A1 (n = 39; 58%), A2 (n = 9; 13%), A3 (n = 6; 
9%);  steatosis: grade 0 (n = 34; 50%), grade 1 (n = 17; 25%), grade 2 (n = 11; 16%) grade 
3 (n = 6; 9%). Three patients had only fibrosis (F1), two patients only inflammation (A1) 
and four patients only steatosis (grade 1: n = 2; grade 3: n = 2). Spearman correlation 
coefficients and multiple regression coefficients between fibrosis, inflammation and 
steatosis and the diffusion parameters and are shown in tables 14 and 15.  A moderate 
negative correlation was observed between steatosis and the pure diffusion coefficient (r = 
- 0.5, P < 0.0001). The correlation between the pure diffusion coefficient and fibrosis was 
weak (r = - 0.3, P = 0.01). Inflammation showed a weak negative correlation with the 
perfusion fraction (r = - 0.3, P = 0.04) and none with the other parameters. In the multiple 
regression model, only steatosis showed an independent influence on the diffusion 
parameters and this was found exclusively for the pure diffusion coefficient (RC = - 0.4, P 
= 0.0003) (Fig. 50). Spearman correlation coefficients and multiple regression coefficients 
between fibrosis, inflammation and steatosis and the viscoelastic parameters are shown in 
tables 16 and 17. Fibrosis showed a univariate correlation with the shear and the storage 
moduli (G*: r = 0.6; G’: r = 0.5; P < 0.0001), and a weak correlation with the loss 
modulus (G’’: r = 0.4, P = 0.001). Inflammation showed a weak correlation (r = 0.2 - 0.4) 
with each viscoelastic parameter, as did steatosis. In the multiple regression model, 
fibrosis was a significant independent factor influencing the measured shear and storage 
modulus (G*: RC = 0.6; G’: RC = 0.5; P < 0.0001) (Fig. 51). The multivariate correlation 
coefficient was weaker between fibrosis and the loss modulus (RC = 0.4, P = 0.0002). 
Steatosis showed a weak correlation (RC = 0.3, P < 0.05) on the shear and storage moduli 
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and inflammation had no effect on the measured viscoelastic parameters.  
 
 
Table 14. Univariate Spearman rank correlations between diffusion parameters and fibrosis, 
inflammation and steatosis  
 
 Fibrosis Inflammation Steatosis 
D (10-3 x mm2/s) P = 0.01 
r = - 0.3 
 
P = 0.16 P = 0.0001 
r = - 0.5 
 
D* (10-3 x mm2/s) P = 0.5 
 
P = 0.8 P = 0.14 
f (%)           P = 0.2    P = 0.04 
     r = - 0.3 
 
  P = 0.7 
 
 
 
 
 
 
     Table 15. Multiple regression analysis between diffusion parameters and fibrosis, inflammation 
and steatosis 
 
 Fibrosis Inflammation Steatosis 
D (10-3 x mm2/s)  nim 
 
nim P = 0.0003 
RC = - 0.42 
 
D* (10-3 x mm2/s) nim 
 
nim nim 
f (%)          nim                  nim 
 
   nim 
 
           
          nim, not in model. 
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Table 16. Univariate Spearman rank correlations between viscoelastic parameters and fibrosis, 
inflammation and steatosis  
 
 Fibrosis Inflammation Steatosis 
G* 
(kPa) 
P < 0.0001 
r = 0.6 
  P = 0.001 
  r = 0.4 
 
P = 0.05 
r = 0.2 
 
G’ 
(kPa) 
P < 0.0001 
r = 0.5 
 
            P = 0.01 
r = 0.3 
P = 0.003 
r = 0.4 
 
G’’                     P = 0.001                          P = 0.02                      P = 0.08 
(kPa)                    r = 0.4                             r = 0.3 
 
 
    Table 17. Multiple regression analysis between viscoelastic parameters and fibrosis, inflammation 
and steatosis  
 
         nim, not in model 
 
 
 
 
 
 
 
 
 Fibrosis Inflammation Steatosis 
G* 
(kPa) 
P < 0.0001 
RC = 0.6 
                    nim 
 
P = 0.02 
RC = 0.3 
 
G’ 
(kPa) 
P < 0.0001 
RC = 0.5 
                 nim P = 0.01 
RC = 0.3 
 
G’’                P = 0.0002                               nim                              nim 
(kPa)               RC = 0.4 
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   a                           b 
 
Figure 50. Parametric color maps of true diffusion coefficient (10-3 mm2/s) in two patients with viral 
hepatitis. METAVIR scoring and steatosis grading are: a) F1A0 steatosis grade 0, b) F1A0 steatosis grade 
3. The mean values for the true diffusion coefficient are significantly decreased by the presence of steatosis. 
 
 
 
a     b    c 
 
Figure 51. Parametric color maps of the complex shear modulus (kPa) in three patients with viral 
hepatitis. METAVIR scoring and steatosis grading are: a) F1A1 steatosis grade 0, b) F1A1 steatosis grade 2 
and c) F3A2 steatosis grade 0. The mean values for the complex shear modulus are not significantly 
modified by the presence of steatosis: images a) G* = 2 kPa and b) G* = 1.8 kPa; but there is an increase in 
the measured complex shear modulus in the patient with higher liver fibrosis staging: image c) G* = 3.1 kPa. 
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Discussion 
 
In this prospective clinical study we measured the correlation between liver fibrosis, 
inflammation, steatosis and the diffusion and viscoelastic parameters, in patients with viral 
hepatitis and nonalcoholic fatty liver disease. Our results in patients with chronic liver 
diseases show that the measurements of shear and storage moduli are mostly influenced by 
changes in liver fibrosis, while liver steatosis mainly influences the measurements of the 
pure diffusion coefficient and to a lesser extent those of the mechanical parameters.  
Diffusion-weighted imaging has been increasingly used to assess liver fibrosis. In fact, 
previous studies have shown that the apparent diffusion coefficient values decrease in 
fibrotic and cirrhotic livers compared to the normal liver tissue, which is mainly related to 
the decrease in capillary perfusion (81, 82, 85, 87). However, there are still limited data 
regarding the specific influence of histopathologic findings such as inflammation and 
steatosis on the measured intravoxel incoherent motion parameters in patients with liver 
fibrosis. In our study, we found a significant negative correlation between the pure 
diffusion coefficient and the presence of liver steatosis. Moreover, steatosis was the only 
histopathologic factor that independently influenced the true diffusion coefficient. These 
results are in agreement with the recently reported findings by Leitão et al (146) and Guiu 
et al (147) in patients with pure steatosis and nonalcoholic fatty liver disease, respectively. 
Although an inverse correlation was found between liver fibrosis and the pure diffusion 
coefficient no independent influence was seen for fibrosis. Thus, our work clearly 
highlights that steatosis is definitively a confounding factor, that overweighs fibrosis when 
present. We did not see any univariate or multivariate correlation for the perfusion-related 
diffusion coefficient, which is not surprising since this is the most unstable parameter, has 
poor reproducibility and is prone to noise (83, 125).  
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It is known that the increase in liver stiffness is well correlated with the degree of fibrosis 
(103).  However, conflicting data still exists regarding the influence of inflammation and 
steatosis, which frequently coexist with liver fibrosis in chronic liver disease, on the 
measurements of liver stiffness. In previous studies, inflammation has been reported to 
have no effect (95, 160, 161) or to increase the biomechanical parameters (102, 162 - 
165). The differences in these results are probably related to the study population. In 
studies including an elevated proportion of high grade inflammation, especially in studies 
of patients with acute hepatitis or acute flares in chronic HBV infection, inflammation 
significantly increases the liver stiffness. In populations with more chronic diseases and 
less advanced grades of inflammation, this effect is not seen. Weak correlations between 
inflammation and the biomechanical parameters were observed in our study at univariate 
analysis and no significant effect of inflammation was seen at multivariate analysis. In 
contrast, in the study of Fraquelli et al. (164) inflammation was a significant confounder 
on stiffness measurements at multivariate analysis. In their study population, 54% of the 
patients had an inflammation grade < 2, whereas 46% were A ≥ 2. Moreover, when we 
excluded the patients with ALT (Alanine Transaminase) > 2 the upper limit of normal, the 
correlation between inflammation and mechanical parameters disappeared. This shows 
that the relationship between stiffness measurements and fibrosis stage in patients with 
high ALT levels should be regarded cautiously. Therefore, it has been recommended to 
correct the stiffness measurements in patients with increased ALT levels. However, this 
correction is not yet used in clinical practice since different cut-off values for normal and 
elevated ALT levels have been proposed in order to adjust the inflammation-induced 
overestimation of fibrosis stage (166). 
The influence of steatosis on the biomechanical parameters is also debated. Steatosis has 
been reported not to modify (95, 160,161, 167) to increase (103, 164) or even to decrease 
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the liver mechanical parameters (168). Again these differences may be explained by 
differences in steatosis grade between the populations, but also by differences in liver 
diseases with steatosis. Indeed, Fraquelli et al. (164) reported increases in liver stiffness 
with steatosis in patients with HCV infection, but not in patients with HBV or NAFLD. 
They explained this condition by the increase of inflammation and fibrosis that is caused 
by liver steatosis in patients with HCV. The decrease of stiffness observed in the study of 
Gaia et al. (168) in patients with steatosis is more difficult to explain, but may be caused 
by suboptimal measurements of transient elastography in obese patients. In our study, we 
observed that steatosis correlated weakly with the biomechanical parameters at univariate 
analysis and had a modest influence at multivariate analysis. We can conclude from our 
study that the measuremants of the biomechanical parameters are mainly influenced by the 
stage of liver fibrosis, whereas the measurements of the diffusion parameters are mainly 
influenced by liver steatosis. This is a strong argument for using MR elastograghy rather 
than DW-MRI to stage liver fibrosis. These results are in agreement with those of Wang et 
al. (97) who showed with ROC analysis the superior diagnostic performance of MR 
elastography relative to DW-MR imaging in staging liver fibrosis.    
This study has some limitations that need to be acknowledged. First, the number of 
patients in this study, albeit acceptable, included only a small group with severe 
inflammation. However, this is a true reflection of the population with chronic liver 
disease. Our observations that inflammation has no influence on viscoelastic parameters 
may not be valid in patients with ALT flares, which highlight the need for its 
measurement. Secondly, we acquired free-breathing echo-planar diffusion-weighted 
imaging and physiological motion is always a concern when studying the microscopic 
displacement of protons. However, it was recently proposed that free breathing with 
multiple acquisitions is superior to complex gating techniques (75).  
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In conclusion our work confirms that the measured diffusion parameters are significantly 
modified by the presence of liver steatosis and that there is clearly an advantage in using 
MR elastography parameters when assessing patients with liver fibrosis, since these are 
less sensitive to the confounding effects of inflammation and steatosis. 
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7.1. Experimental Animal Study 
7.1.1. Molecular Imaging of Liver Fibrosis with EP-2104R: a Feasibility Study in Rats  
 
Introduction 
Liver damage leads to the development of fibrosis as a paradigm of the wound healing 
process, since increased coagulant factors such as fibrin and fibrinogen have been 
described in chronic liver disease, despite the prolonged conventional coagulation tests 
(169 - 173). Furthermore, haemophiliac patients with chronic viral hepatitis demonstrate a 
slow progression of liver fibrosis (174). Currently, there are no effective antifibrotic drugs 
clinically available but the association between hypercoagulation and increased fibrosis 
seems to indicate that interference with the coagulation cascade may in fact reduce liver 
fibrosis. 
EP-2104R is a novel fibrin-specific MR contrast agent that combines strong fibrin 
binding, fibrin selectivity, and high molecular relaxivity (175). EP-2104R was found to be 
effective at providing positive contrast enhancement in preclinical models of arterial and 
venous thrombosis and pulmonary emboli (176 - 180). Moreover, EP-2104R has already 
entered a phase II clinical trial and confirmed the increased specificity and sensitivity to 
detect thrombo-embolic disease in patients and without any serious adverse effects (180). 
This contrast agent demonstrated increased usefulness in both fresh as well as aged clots. 
However, the efficacy of EP-2104R in the detection of liver fibrosis was never assessed. 
Therefore, the purpose of this feasibility study was to determine whether fibrin-targeted 
dynamic MRI could be used as a noninvasive biomarker to detect liver fibrosis in a rat 
model.
131  
Materials and Methods 
 
Animal Model 
All experiments were performed in accordance with the NIH (National Institutes of Health) 
Guide for the care and use of laboratory animals and were approved by the Athinoula A. 
Martinos Center care and use committee. Male Wistar rats (Charles River Laboratories, 
Wilmington, MA) were given weekly intraperitoneal injections of 100 mg/kg 
diethylnitrosamine (DEN; Sigma, St. Louis, MO) for 5 weeks (n = 5), defined as the 
moderate fibrosis group, and 9 weeks (n = 5), corresponding to the cirrhosis group. Control 
animals received PBS (phosphate buffered saline) for 4 weeks (n = 5) and 8 weeks (n = 5).  
 
Probe 
EP-2104R (EPIX Pharmaceuticals, Lexington, MA) represents a new class of MR imaging 
contrast agents in which a specific protein is targeted for imaging. EP-2104R comprises a 
fibrin-binding peptide (11 amino acid peptide) coupled to 4 gadolinium DOTA-like 
chelates (Fig. 52). EP-2104R binds equally to 2 sites on human or rat fibrin (Kd = 1.7 or 
1.8 µmol/L, respectively) and has excellent specificity for fibrin compared with serum 
proteins, e.g., > 100-fold affinity relative to fibrinogen and > 1000-fold relative to serum 
albumin (175). The relaxivity of EP- 2104R bound to fibrin at 37 °C and at 1.4 Tesla is 
71.4 mM-1s-1 (17.4 mM-1 s-1 by [Gd]), about 25 times higher than that of Gd-DOTA 
measured under the same conditions (175). EP-2104R was provided as a sterile, white 
lyophilized powder that was reconstituted at the site and administered to the animals at a 
dose of 1µL/g (20 µmol Gd/kg). 
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Figure 52. Chemical structure of EP-2104R. Reproduced from [175]. 
 
MR imaging and analysis 
Rats were anesthetized with 2.5% isoflurane. Intraperitoneal injection of ketamine at a 
dose of 100 mg/kg was given as maintenance dose. The tail vein was cannulated for 
intravenous delivery of the contrast agent. Magnetic resonance imaging was performed in a 
1.5-T MR unit (Magnetom Avanto Syngo, Siemens Healthcare, Erlangen, Germany) with a 
high-resolution 4-channel wrist coil. The animals were placed in prone position in the 
scanner and body temperature was approximately kept at 37.5 °C by a heating device. 
The imaging protocol included pre and post contrast imaging with the 3D T1-weighted 
VIBE sequence with the following parameters: repetition time/echo time 7/3.27 ms, 77-
mm field of view, matrix 192 x 192, in-plane resolution 0.4 mm, 30 transverse slices per 
slab, slice thickness 1 mm, 8 averages. The acquisition time was 3 min and 8 s. The T1 
VIBE sequence post dynamic imaging was repeated out to 30 min. For the dynamic 
imaging a 2D multislice fast low angle shot sequence (FLASH) was used with the 
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following parameters: repetition time/echo time 5/2.17 ms, 80-mm field of view, matrix 61 
x 61, in-plane resolution 1.3 mm, 1 transverse slice, slice thickness 3 mm, 4 averages. The 
total acquisition time was 6 min, 2 min baseline imaging and 4 min dynamic imaging. 
A radiologist, with 5-year experience in MR imaging, drew a region of interest of ± 0.8 
cm2 in the right lobe of the liver of each rat. The signal intensity of the region of interest 
was measured using OsiriX imaging software (v.3.9.4 - 32 bits) with a specific homemade 
plugin (fit toolbox), and was exported to Microsoft Excel with Solver software (Fig. 53). 
Noise was quantified as the standard deviation of the signal intensity in the air adjacent to 
the animal. Contrast-to-noise ratio (CNR) was calculated as the signal intensity difference 
between liver and skeletal muscle. 
 
 
 
 
Figure 53. MR images before (a and c) and after EP-2104R injection (b and d) with regions of interest 
in rat with liver fibrosis (a and b) and control rat (c and d). Remaining signal intensity enhancement is 
observed in rat with liver fibrosis 30 min after EP-2104R injection. 
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Tissue Analysis 
Several organs (liver, lungs, pancreas, spleen, kidney, muscle, heart, bone, tail, brain, fat 
and intestines) and blood were harvested 45 min after imaging. Formalin-fixed samples 
were embedded in paraffin, cut into 5 mm-thick sections and stained with sirius red 
according to standard procedures. The stained sections underwent blinded review by a 
board certified hepatobiliary pathologist to score the amount of liver fibrosis according to 
the METAVIR score (150). Gadolinium was quantified in tissue acid digests by 
inductively coupled plasma-mass spectrometry (Agilent 7500 Series, Agilent 
Technologies, California, USA) using dysprosium as internal standard. Gadolinium 
concentrations in the livers were normalized to the gadolinium concentration in blood to 
compensate for variations in the injected doses, and expressed as the percentage of the 
injected dose per wet weight of tissue.  
 
 
Statistical Analysis 
The differences between both groups of animals (control vs diseased) were assessed with 
Student’s t test. A P value ≤ 0.05 was considered statistically significant. Statistical 
analysis was performed with the MedCalc software (MedCalc, Mariakerke, Belgium). 
 
Results 
During this feasibility study the rats of the cirrhotic group died at week 7 due to a 
nematode infestation in the animal house. One of our control rats also died during MR 
imaging. The final imaged population consisted of 4 rats with 5 weeks PBS injection 
(control group) and 5 rats with 4 weeks DEN injection (moderate fibrosis group). The 
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histopathological analysis revealed a normal liver parenchyma in the control group and the 
following fibrosis distribution for the diseased group: one rat had mild fibrosis (F1) and 4 
rats moderate fibrosis (3 F2 and 1 F3) (Fig. 54). 
 
 
 
Figure 54. Liver slices stained with sirius red in four rats. Corresponding fibrosis stages are indicated in 
the upper left corner of each image.  
 
 
 
Since one rat had only mild fibrosis after 4 week injections of DEN, it was removed from 
the analysis of the fibrosis group. The mean time to peak enhancement was significantly 
longer in fibrotic rats (22.4 s vs 14.4 s; P = 0.002) (Fig. 55).   Signal intensity enhancement 
was still observed in the liver parenchyma 7 min after EP-2104R injection in the rats with 
liver fibrosis, but not in the control rats (mean enhancement 19.3 % vs 1%; P = 0.01) (Fig. 
56).  The prolonged retention of EP-2104R in the liver parenchyma of the rats with liver 
fibrosis was also shown by the lack of significant signal intensity decrease in the rats with 
liver fibrosis between 10 and 30 min after EP-2104R injection. The liver percentage of 
injected dose of gadolinium was higher in the rats with liver fibrosis than in the control 
rats, but the difference was not significant (Fig. 57). We also compared the increase in 
CNR at 7 min after EP-2104R injection relative to the baseline. Although the measured 
CNR at 7 min was higher in the rats with liver fibrosis relative to the normal rats, a 
statistically significant difference was not found.   
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Figure 55. Time to peak enhancement (s) between control rats and rats with liver fibrosis. Time 
to peak enhancement is significantly higher in rats with liver fibrosis (P = 0.002) 
 
         
Figure 56. Signal enhancement in control rats and rats with liver fibrosis 7 min after EP-2104R 
injection.  Signal enhancement is significantly higher in rats with liver fibrosis (P = 0.01). 
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Figure 57. Percentage of injected dose per wet weight of tissue (blood, lungs and liver) in control rats 
and rats with liver fibrosis. The values represented are normalized by liver/blood and lung/blood ratio. 
There is a trend to higher percentage of injected dose in the liver of rats with liver fibrosis relative to control 
rats.  
 
 
Discussion 
 
In this feasibility study we were able to differentiate murine livers with moderate DEN 
induced fibrosis from normal livers with the novel fibrin-specific contrast agent EP-2104R. 
The time to peak enhancement with this contrast agent and the signal decrease in the liver 
were significantly prolonged in rats with liver fibrosis relative to controls. 
The rationale of using a fibrin-targeting agent in liver fibrosis is based on the presence of a 
procoagulant status in liver fibrosis.   For a long time clinicians thought that patients with 
cirrhosis were protected against thrombotic events. However, several studies have shown 
that patients with advanced hepatic fibrosis have a procoagulant state that places them at 
risk for thrombo-embolic episodes (174). Two complementary theories could explain how 
the coagulation cascade may be related with liver fibrosis (170, 174). The first one 
(parenchymal extinction theory) postulates that microthrombi in branches of the hepatic 
and portal veins are induced by the adjacent necroinflammatory activity. The resulting 
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imbalance between inflow and outflow leads to congestion and tissue ischaemia with 
resulting parenchymal extinction and replacement by fibrous tissue (Fig. 58). The second 
theory (direct stellate cell activation) proposes that the aggression to the liver parenchyma 
increases the expression of thrombin receptor PAR-1 and of tissue factor, which will 
initiate the coagulation cascade by increasing thrombin expression. The binding of 
thrombin to PAR-1 leads to direct stellate cell activation and fibrinogenesis (Fig. 58). 
 
 
Figure 58. PAR-1 mediated actions of thrombin in stellate cell activation. Inflammation within the 
hepatic parenchyma increases expression of tissue factor, a key initiator of the coagulation cascade, and the 
thrombin receptor, PAR-1. Inflammation thus primes both the generation of thrombin and its down-stream 
signaling activity. In the presence of the FvL (factor V Leiden) mutation, the normal thrombin/ 
thrombomodulin negative feedback loop via activated protein C (APC) that limits thrombin production is 
ineffective. This allows thrombin generation to proceed unchecked in a hepatic environment that is already 
sensitized for PAR-1 mediated stellate cell activation both directly and via platelet released PDGF (platelet-
derived growth factor). (TM, thrombomodulin). Reproduced from [174]. 
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The fibrin-targeted agent presented here has the potential to be a complementary approach 
to detect liver fibrosis. We were, nonetheless, somewhat surprised by the small 
concentrations of the probe in the liver. This might be explained by probe binding in other 
organs.  We analyzed blood, liver and lung with inductively coupled plasma-mass 
spectrometry and also found EP-2104R in the lung. This is not totally surprising because 
pulmonary and liver fibrosis have the same pro-coagulant and pro-fibrotic factors. 
Moreover, DEN is able to induce lung injury (181 - 183). The kinetic properties of EP-
2104R found in this study were significantly different between controls and rats with 
fibrosis, even though we only assessed a group with moderate fibrosis.  Moreover EP-
2104R offers a genuine clinical potential since in phase II trials for thrombi detection, no 
serious adverse events were observed in patients.   EP-2104R also has a high relaxivity at 
common clinical field strengths (1.5 and 3 T). Although with this work we tried to 
demonstrate the feasibility of using EP-2104R as fibrin targeting agent in liver fibrosis, this 
study has some limitations that need to be acknowledged. First, we did not evaluate EP-
2104R in rats with liver cirrhosis. Second, we only analyzed the concentrations of the 
probe in the liver, lung and blood. Third, fibrin immunohistochemistry of liver slices was 
not performed. These points will however be addressed in future studies. 
In conclusion, the results of our study in rats with DEN induced liver fibrosis suggest that 
the fibrin-targeting agent EP-2104R may be useful for distinguishing between normal liver 
parenchyma and liver fibrosis.  
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7.2. Clinical Studies 
7.2.1. Accuracy and Reproducibility of ShearWave Elastography to Assess Liver Fibrosis 
in Patients with Chronic Viral Hepatitis and Nonalcoholic Fatty Liver Disease  
 
Introduction 
 
Liver biopsy with histopathological quantification is the current gold standard to stage 
fibrosis. However, this method is invasive, not easily accepted by the patient, provides 
only a semiquantitative evaluation and suffers from pooling errors in the assessment of 
diffuse and heterogeneous liver diseases (4, 50). The need for novel noninvasive imaging 
biomarkers is a real clinical challenge. Although serum biomarkers have been proposed to 
stage fibrosis, their diagnostic value still remains debated for intermediary stages of 
fibrosis (23, 37, 44, 46, 50). Transient elastography was the first ultrasound-based method 
implemented in clinical practice showing that liver stiffness rises along with increasing 
fibrosis stages (23, 37, 43, 44). However, this method has limitations because 
measurements are difficult to obtain in at least 16% of the patients and are often impossible 
to obtain in patients with ascites or who are obese (23). Shearwave elastography (SWE) is 
a new ultrasound-based method with ultra rapid image acquisition under evaluation in the 
clinical setting (58, 59). Very few studies have evaluated SWE and mostly only included 
hepatitis C patients, but clinicians are already confronted with conflicting results (58, 60, 
184). Moreover, reproducibility of the technique has only been assessed in healthy 
volunteers. Therefore, the purpose of this still ongoing work was to (1) determine the 
performance of shearwave elastography to differentiate F0-1 vs ≥ F2 fibrosis stages in 
patients with chronic viral hepatitis and NAFLD and the respective cut-off value, (2) assess 
interobserver reproducibility, (3) evaluate the independent influence of steatosis and 
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inflammation on the measurement of liver stiffness and (4) determine the time it adds to 
routine abdominal ultrasound examinations. 
 
Materials and Methods 
 
Patients and study protocol 
The review board at our institution approved this single-center and prospective clinical 
study and informed consent was obtained for all patients. From March through October 
2012, all consecutive patients 18 years or older, with suspected chronic viral hepatitis or 
nonalcoholic fatty liver disease, scheduled for liver biopsy were enrolled for this study. A 
total of 50 patients were included in the study protocol that consisted of real-time SWE 
studies using the Aixplorer US system (SuperSonic Imagine, Aix-en-Provence, France) 
with a convex broadband probe (SC6-1). Two patients were excluded because they missed 
the scheduled appointment. The final study population consisted of 48 patients, 21 women 
and 27 men, with a mean age of 40 years for women (range: 29 - 66 years) and 44 years for 
men (range: 24 - 71 years) and mean body mass index of 26.1 kg/m2 (range: 20 – 40 
kg/m2). Seventeen patients had viral hepatitis B, 22 viral hepatitis C and 9 nonalcoholic 
fatty liver disease. A board certified hepatobiliary pathologist who was unaware of the 
imaging results performed the histopathologic analysis of all liver specimens. Fibrosis and 
inflammation were documented according to the METAVIR or NAS scoring systems (27, 
150, 151) and steatosis was graded according to the Brunt classification (4), as previously 
explained in Chapter II, sections 2.2.1. and 2.2.2.. The mean interval between biopsy and 
SWE was 14 days (range: 0 - 60 days). 
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Supersonic Shear Imaging 
All measurements were performed in the right lobe of the liver with the patient lying in a 
dorsal decubitus position. The right arm was always maintained in abduction to enlarge the 
intercostal space as much as possible and to increase access to the right hypochondrium. 
The patient was asked to be fasting, as before conventional ultrasound imaging, and to 
maintain either a shallow breathing or apnea when asked. All measurements were 
performed between 2 and 7 cm of the surface of the liver to prevent reverberation artifacts 
beneath the Glisson’s capsule and ensure good wave penetration.  Observer 1 (10-year 
experience in abdominal ultrasonography) obtained liver stiffness measurements from a 
circular region of interest, 20 - 22 mm in diameter, avoiding large vessels or focal liver 
lesions. The mean value of three consecutive measurements in segments V, VII and VIII 
was used for statistical analysis. Observer 2 (3-year experience in abdominal 
ultrasonography) blinded to the results of observer 1 repeated three measurements only in 
segment V. The resulting liver stiffness was displayed in the circular region of interest as a 
color map and at the right side of the image as maximum, minimum and mean values and 
respective standard deviations (Fig. 25). Measurements were defined as failures when no 
or little signal was obtained in the SWE box. Total time required for the measurements was 
assessed for each patient and observer. 
 
Statistical Analysis 
 
The performance of SWE to distinguish patients with a fibrosis stage ≥ F2 was determined 
by calculating the area under the receiver operating characteristic curve (AUROC).  
Univariate correlations between stiffness measurements and fibrosis, inflammation and 
steatosis were calculated with Spearman rank correlation coefficients (r) (158). In addition, 
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fibrosis, inflammation and steatosis were introduced as independent variables in a 
multivariate regression model to assess their independent effect on the measured parameter 
(159). With this model multivariate regression correlations (RC) were calculated. Groups 
of patients with different inflammation grades among the same fibrosis stage were 
compared with the Kruskal-Wallis test. Interobserver reproducibility was calculated using 
intraclass correlation coefficients. A P value ≤ 0.05 was considered statistically significant. 
Statistical analysis was performed with the MedCalc software (MedCalc, Mariakerke, 
Belgium). 
 
Results 
 
In the 48 patients the histopathologic analysis revealed the following distribution. Fibrosis 
stage: F0 (n = 7), F1 (n = 18), F2 (n = 7), F3 (n = 8), F4 (n = 8);  inflammation grade: A0 
(n = 9), A1 (n = 23), A2 (n = 11), A3 (n = 5);  steatosis grade: S0 (n = 23), S1 (n = 9), S2 
(n = 11), S3 (n = 5). The univariate correlations between stiffness on one hand and fibrosis, 
inflammation and steatosis on the other were always significant but only fibrosis had a 
correlation coefficient above 0.5 (Fibrosis: r = 0.63, P < 0.0001; Inflammation: r = 0.40, P 
= 0.005; Steatosis: r = 0.35, P = 0.02). Although measured stiffness values within the same 
fibrosis stage showed an increasing trend with severe inflammation grade, no significant 
statistical difference was found between groups (Table 18).  Only liver fibrosis was found 
to have an independent effect on the liver stiffness (RC = 0.69, P < 0.0001). Using liver 
biopsy as the reference examination we found that a SWE cut-off value of 10.3 kPa 
provided the diagnosis of ≥ F2 with 80% sensitivity and 95% specificity. The AUROC was 
0.92, P < 0.0001 (Fig. 59). The real-time SWE examination lasted approximately 7 
minutes per patient for observer 1 (three segments measured) and 3 minutes for observer 2 
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(one segment measured). No measurement was classified as failure (Figs. 60, 61). The 
intraclass correlation coefficient for the interobserver agreement was 0.99 (95 % CI, 0.98 - 
0.99). 
 
Table 18. Mean SWE stiffness and standard deviation according to fibrosis stage and inflammation 
grade  
 
 
 
Note: Stiffness values within the same fibrosis stage showed an increasing trend with severe inflammation 
grade but no statistically significant difference was observed.  
 
 
 
Figure 59. Real-time SWE AUROC (0.92, P < 0.0001) to differentiate between F0-1 vs F2-4 fibrosis 
stages. 
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Figure 60. SWE stiffness (26.9 kPa) in a patient with chronic hepatitis B. METAVIR score was A2F4 
and no steatosis was identified on the liver slice.  
 
 
 
 
Figure 61. SWE stiffness (6.3 kPa) in a patient with chronic hepatitis C. METAVIR score was A2F0 and 
no steatosis was identified on the liver slice. 
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Discussion  
 
In this preliminary prospective clinical study, which included patients with viral hepatitis 
and NAFLD, we have found that only fibrosis has an independent effect on the liver 
stiffness measured with SWE. Moreover, SWE had excellent interobserver reproducibility 
and could accurately differentiate patients with F0-1 vs F2-4 fibrosis stages with an 
AUROC of 0.92 (P < 0.0001).  
Real-time SWE is a novel ultrasound-based elastography method under evaluation for the 
assessment of liver fibrosis in patients with chronic liver diseases. Few studies have 
assessed the performance of SWE (58, 60, 184) and apart from the recent study by Poynard 
et al (184) which did not use liver biopsy as reference examination, the evaluation was 
limited to patients with chronic hepatitis C. Ferraoili et al (60) recently reported results 
similar to ours in a population of patients with hepatitis C with AUROCs of 0.92 and 0.99 
respectively for F ≥ 2 and F4.  
In our study, no measurement was classified as having failed, even in the 9 patients with a 
BMI higher than 30 kg/m2. We do acknowledge that a learning curve is needed for SWE as 
for all imaging methods but we do not think that 100 examinations should be performed to 
be an experienced operator, as reported by Poynard et al (184). Indeed, in contrast to 
Fibroscan, SWE offers the advantage of being incorporated in a common ultrasound device 
allowing direct comparisons between SWE and B-mode images. Since both operators in 
our study were experienced in abdominal ultrasound examinations, the learning curve for 
SWE was rapid and both operators felt confortable performing SWE examinations after 15 
patients, which comes in agreement with the findings by Ferraioli et al (185).  
Although this is an ongoing study and at the time of this thesis limited to 48 patients, two 
of our patients, both diagnosed with NASH, were puzzling. Patient 1 had a mean liver 
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stiffness of 13.9 kPa while patient 2 had 7.9 kPa stiffness (Figs 62, 63). However, the 
histopathologic score classified both patients as having mild fibrosis (F1) and severe 
inflammation (A3). Steatosis was also classified as grade 2 for both patients (34 - 66 %).  
 
 
Figure 62. SWE stiffness (13 kPa) in a patient with NASH.  
 
 
The reason for the discrepancy in liver stiffness is not completely understood because the 
SWE studies were considered valid by the two observers each time, which also obtained 
very similar liver stiffness values. Moreover, apart from the different gender, no significant 
clinical differences (e.g. BMI, age, transaminases, comorbidities) were found between 
them. Additionally, the pathologist reviewed the histological slices and made no changes in 
the previously attributed score. Although these results are still preliminary, we might 
hypothesize that in patient 1 fibrosis was more heterogeneously distributed and in this case 
the limited parenchymal evaluation of liver biopsy underscored the patient. Moreover, 
these two patients also participated in the study described in chapter VI and the measured 
monofrequency (50 Hz) MRE storage modulus (≈ elasticity) was also higher for patient 1.  
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Figure 63. SWE stiffness (7.9 kPa) in a patient with NASH.  
 
Our study has limitations that need to be acknowledged. First, the number of included 
patients is small. However, this is an ongoing study and we plan to include more than 100 
patients. Second, since none of our patients had ascites we were not able to assess the 
potential influence of this factor on the SWE measurements.  
In conclusion, this is the first study to assess the performance and reproducibility of SWE 
in patients with chronic viral hepatitis B, C and NAFLD, using liver biopsy as gold 
standard. We found that SWE can accurately detect patients with a fibrosis stage ≥ F2, has 
excellent interobserver reproducibility and it can easily be incorporated in the routine 
abdominal ultrasound examinations. Moreover, only fibrosis was found to have an 
independent effect on liver stiffness.  
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7.2.2. Evaluation of Multifrequency MRE Wavelength Exponent in Patients with Liver 
Fibrosis and Inflammation:  a Feasibility study 
 
Introduction 
 
Magnetic Resonance Elastography (MRE) is sensitive to changes induced by fibrosis in the 
mechanical properties of the liver and is now acquiring a more relevant place in the clinical 
setting (95 – 97, 186). Liver inflammation is frequently associated with fibrosis but so far a 
noninvasive imaging biomarker to detect and differentiate inflammation grades has not 
been found. Standardization for MRE studies has been difficult because the behavior of 
compressional and shear waves is influenced by the frequency of excitation applied in the 
first place, thus the obtained viscoelastic values are difficult to compare (98, 186 - 188). 
This frequency-dependent wave attenuation and dispersion at the tissue and cellular level 
can nevertheless be explained by a common wave equation modeled by a power law, 
therefore excluding frequency dependence (187). Asbach et al (98) used a frequency-
independent shear modulus to evaluate patients with liver fibrosis and found that this 
parameter did not have a superior performance compared to the monofrequency evaluation. 
However, the authors did not assess the influence of inflammation on their measured 
parameters neither did they study the behavior of the wavelength. Therefore, the purpose 
of this still ongoing study was to evaluate the performance of the frequency-independent 
wavelength exponent in patients with liver fibrosis and inflammation. 
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Materials and Methods 
 
The review board at our institution approved this single-center and prospective clinical 
study and written informed consent was obtained for all patients. From March through 
October 2012, all consecutive patients 18 years or older with untreated chronic viral 
hepatitis scheduled for liver biopsy were enrolled for this study. A total of 35 patients were 
included in the study protocol, which consisted of multifrequency MRE on a 1.5-T MR 
unit (Philips Healthcare, Best, The Nederlands) using a gradient-echo sequence with the 
following parameters: TR/TE=112 ms/9.6 ms, 320-mm field of view, 9 transverse slices, 4 
mm
3
 isotropic resolution, 3-directional encoding, 8 points per vibration period. The total 
acquisition time was 1m 20s. The simultaneous 28, 56 and 84 Hz mechanical waves were 
induced with an electromechanical transducer placed closed to the liver on the right flank 
of the patient in supine position (Fig. 43). The complex-valued shear modulus was 
calculated by demodulation and local inversion of the linear viscoelastic 3D wave equation 
and converted into wavelength (λ, mm). The frequency dependence modeled by a power 
law was assessed as the wavelength exponent parameter (ϒλ). Ten patients were excluded 
because of technical problems. The final study population consisted of 25 patients, 7 
women and 18 men, with a mean age of 48 years (range: 31 - 68 years). Eight patients had 
chronic hepatitis B and 17 had chronic hepatitis C. An expert hepatobiliary pathologist 
who was unaware of imaging results performed the histopathologic analysis of all liver 
specimens. Fibrosis and inflammation were documented according to the METAVIR 
scoring system, as described in chapter II, section 2.2.1. (150). The mean interval between 
biopsy and MRE was 24 days (range: 4 - 60 days).  
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Statistical Analysis 
 
Patients with different inflammation grades and fibrosis stages were compared with the 
Kruskal-Wallis test. The performance of ϒλ to distinguish between A0-1 vs A2-3 was 
determined by calculating the area under the receiver operating characteristic curve 
(AUROC). A P value ≤ 0.05 was considered statistically significant. Statistical analysis 
was performed with the MedCalc software (MedCalc, Mariakerke, Belgium). 
 
Results  
 
Values are presented as mean ± standard deviation. In the 25 patients the histopathologic 
analysis revealed the following distribution. Fibrosis stage: F0 (n = 2), F1 (n = 13), F2 (n = 
3), F3 (n = 7); Inflammation grade: A0 (n = 5), A1 (n = 15), A2 (n = 4), A3 (n = 1). The 
wavelength exponent decreased with increasing inflammation grades and the difference 
was statistically significant between A0 and A2 (P < 0.01) (Fig. 64). Using liver biopsy as 
the reference standard we found that a cut-off value of -0.43 for ϒλ provided an accurate 
separation of inflammation grades A0-1 from A2-3 with a sensitivity and specificity of 
100% and 85%, respectively. The AUROC was 0.95 (Fig. 65).  Although wavelength 
exponent could also differentiate patients with fibrosis stages F0-1 vs F2-3 (AUROC 0.93), 
when examining the subgroups of patients within the same fibrosis stage, the decrease in 
ϒλ as a function of the inflammation grade was still systematically observed, although no 
statistical significance was observed in this feasibility pool of 25 patients (Fig. 66, Table 
19) 
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Figure 64. Wavelength exponent values among different inflammation grades. 
 
 
 
 
Figure 65. MRE wavelength exponent AUROC (0.95, P < 0.0001) between inflammation grades A0-1 
vs A2-3. 
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Figure 66. Wavelength exponent color scale according to the fibrosis stages and inflammation grades. n 
= number of patients per corresponding fibrosis stage and inflammation grade. 
 
 
 
 
 
Table 19. Mean wavelength exponent values and standard deviations according to the fibrosis stages 
and inflammation grades 
 
 
 
Note: wavelength exponent values within the same fibrosis stage showed a decreasing trend with increasing 
inflammation grades but no statistically significant difference was observed. 
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Discussion 
 
In this preliminary prospective clinical study, which included patients with chronic viral 
hepatitis, we have found that the wavelength exponent can accurately differentiate A0-1 
from A2-3 inflammation grades. Moreover, this frequency-independent parameter seems to 
decrease according to the inflammation grade independently of the fibrosis stage. 
Elastography-based methods characterize the mechanical properties of the liver through the 
measurement of viscoelastic parameters. MR elastography measures the whole spatial 
displacement vector, which allows assessment of the wave number and propagation and 
separation of elasticity and viscosity parameters. In fact, assuming that elasticity is the only 
parameter that defines the mechanical behavior of biological tissues will result in 
evaluation errors since their viscous property is being ignored (92, 98). Even though MRE 
is progressively acquiring a new place in the assessment of liver fibrosis, comparisons 
among obtained results are difficult and MRE is still far from standardization. Several 
studies have shown that both healthy and diseased liver display a frequency-dependent 
elastodynamic behavior, which also depends upon the postprocessing model used (98, 188 
- 191). Therefore, any specific viscoelastic parameters have to be given in the context of 
the underlying model and detailed by the frequency of excitation applied. One way to 
overcome this drawback is to use frequency-independent viscoelastic parameters.  
Although in the work by Asbach et al (98) the multifrequency MRE (50 - 62.5 Hz) did not 
surpass the previously reported performance of monofrequency for fibrosis staging, this 
was the first and crucial step to MRE standardization. Moreover, MRE has the potential for 
additional increases in technical innovation that will undoubtelly further improved the 
diagnostic accuracy. 
It was already demonstrated in chapter VI that the complex shear modulus and the storage 
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and loss moduli are not able to assess liver inflammation, since the necroinflammatory 
activivity was not found to have any independent effect on these parameters.  In this 
preliminary work we used the multifrequency-derived and frequency-independent 
parameter, wavelength exponent, to assess liver inflammation. The spectrum of 
frequencies used in our work from 28 - 84 Hz matches the range of frequencies already 
used in several studies (95 - 98, 102, 186). The results of this study demonstrate that the 
wavelength exponent can accurately differentiate patients with mild inflammation from 
those with moderate and severe inflammation. Moreover, within the same fibrosis stage we 
found that there was a decreasing trend in the measured wavelength exponent with 
increasing inflammation grades. This could have overall important clinical implications, 
namely in patients with NAFLD since the detection of increased parenchymal activity 
could prevent patients from progressing to severe fibrosis and cirrhosis.  
Our study has limitations. First, the number of included patients is small. However, this is 
still an ongoing study. Second, we did not assess the repeatability of our measurements in 
the same cohort of patients.  
In conclusion, our results show that the wavelength exponent parameter might be an 
important biomarker to assess inflammation in patients with chronic liver disease. 
Moreover, the frequency-independence of this parameter will allow a higher 
standardization and comparison among liver MR elastography studies.  
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Summary, Final Considerations and Perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VIII 
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8.1. Summary 
The results of the present research project have led to the final conclusions: 
 
Chapter IV 
In patients without clinical or imaging evidence of iron overload the quantification of the 
mean liver fat content can be easily performed in routine clinical practice. The use of a 
simple and fast gradient echo sequence, with only three echo times, allows accurate 
mapping of diffuse liver fat with excellent intra- and interobserver reproducibility. This 
mapping technique has the potential for early detection of NAFLD, thus reducing the risk 
of progression to severe stages of this disease. 
 
Chapter V 
Magnetic resonance diffusion-weighted imaging is increasingly used to quantify hepatic 
fibrosis. This IVIM DWI prospective study was the first one to demonstrate, in patients 
with liver biopsy, as the reference examination, that steatosis has a higher impact than 
fibrosis in the measured diffusion parameters. Precaution is therefore warranted when 
using the pure diffusion coefficient in the assessment of liver fibrosis. 
 
Chapter VI 
In this prospective clinical study, two sets of noninvasive MR imaging parameters 
(diffusion and viscoelastic) used to quantify liver fibrosis were put side-by-side and the 
influence of inflammation and steatosis in their final measurements was assessed. The 
results of our study suggest that magnetic resonance viscoelastic parameters are best for 
the evaluation of liver fibrosis since they are less sensitive to the concomitant presence of 
parenchymal inflammation and steatosis. 
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Chapter VII  
Experimental study 
The development of liver fibrosis has been closely related to the activation of the 
coagulation system with increased perisinusoidal fibrin accumulation. This pilot MR 
molecular imaging study in rats with liver fibrosis suggests that the fibrin-binding contrast 
agent EP-2104R has the potential to detect moderate and severe fibrosis. Since this 
compound was already assessed in patients without any serious adverse effects it may be a 
complementary approach to the already existing noninvasive MR-based diffusion and 
viscoelastic biomarkers. 
 
Clinical study 1 
The changes that occur in the extracellular matrix during liver fibrosis have been shown to 
directly influence the mechanical properties of the liver. In this prospective clinical study 
ultrasound-based shearwave elastography was used to evaluate patients with chronic viral 
hepatitis and NAFLD. This imaging technique was found to be accurate in distinguishing 
patients with mild fibrosis from those with moderate and severe fibrosis, exhibiting 
excellent interobserver reproducibility. Inflammation and steatosis were not found to 
influence the measurements of liver stiffness. Moreover, shear wave elastography is easy 
to perform and already implemented in the commonly available ultrasound devices, 
enabling its use as an epidemiologic screening tool in clinical practice. 
 
Clinical study 2 
The recognition of liver inflammation is important for detecting active and evolving 
chronic liver diseases. Until now no imaging biomarker was found for liver inflammation. 
In this pilot study, multifrequency MR elastography was used to assess patients with 
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fibrosis and liver inflammation. Our results suggest that the frequency-independent 
wavelength exponent has the potential to identify and grade liver inflammation. 
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8.2. Final Considerations and Perspectives 
 
The statement “more discoveries have arisen from intense observations of a very limited 
material than from statistics applied to large groups…”, is especially true in imaging 
findings, as the radiologist struggles even more than all other medical specialties to include 
patients in their research studies (192).  
The goal of this thesis was to uncover noninvasive imaging biomarkers to characterize 
chronic liver diseases; i.e., liver fibrosis, inflammation and steatosis. But what does the 
concept of biomarker mean? Biomarkers are by definition measurable parameters that 
allow us to assess normal biological or pathological processes or the response of tissues to 
therapeutic interventions (193, 194). According to the ESR (European Society of 
Radiology) statement on the development of biomarkers, “the clinical value of new 
biomarkers is of the highest priority in terms of patient management, assessing risk factors 
and disease prognosis” (194). New biomarkers should also overcome the important 
limitations of our current gold standard in chronic liver disease; i.e., liver biopsy. 
Quantifying liver steatosis in routine clinical examinations answers many questions and 
has important medical implications.  Undoubtedly, it will allow early detection and follow-
up of NAFLD patients. But we can go even further and widespread this assessment to the 
follow-up of patients under treatment with tamoxifen, antidiabetic drugs, amiodarone, 
antiretrovirals, etc (25, 53). Moreover, accurate and diffuse quantification of liver steatosis 
will help selecting patients that best fit the requirements for liver donors as the presence of 
steatosis in transplanted livers carries an important risk of hepatocellular insufficiency. 
Furthermore, the detection of preoperative liver steatosis is associated with increased 
perioperative risks and even death after major hepatic resection (two or more segments) 
(53, 195 - 199).  
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The noninvasive assessment of liver inflammation and fibrosis/cirrhosis in at-risk groups 
(viral hepatitis, alcoholic and nonalcoholic liver disease, patients under methotrexate 
treatment, etc.) and in the general population is an obvious clinical need. Interestingly, I 
was able to experience in first hand that sympathy and the word “noninvasive” have 
generally a very good acceptance by patients with chronic liver disease. In this project two 
elastography methods, ultrasound-based shear wave elastography and MR elastography, 
were used. They should never be perceived as competitors as they are indeed at two 
different healthcare levels (21) (Fig. 67). Shearwave elastography can and should be 
employed as a screening tool at a secondary level after physical examination and liver 
function tests (simple or composite scores). One of the many advantages over the 
frequently used transient elastography is that this method is already incorporated in 
commonly available ultrasound devices, which are routinely used in the evaluation of 
patients with chronic liver diseases. However, MR elastography is not as widely available, 
is more expensive and belongs to the tertiary level of healthcare. As such, MR 
elastography should further assess the screened and positive patients, as this complex 
method allows more detailed assessment the viscoelastic properties, which can potentially 
characterize liver fibrosis and inflammation (Fig. 68). 
 
 
Figure 67. Levels of care for elastography-based methods in chronic liver diseases. 
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Figure 68. MR biomarkers for the assessment of chronic liver disease as proposed by this project. 
 
Molecular imaging is at the moment relegated to the basic experimental assessment of 
chronic liver diseases, for safety and economical reasons. Even though the MR contrast 
agent studied in this project, as opposed to other vectorized probes, has already entered 
phase II proof-of-concept clinical trials in patients with thombo-embolic disease, the FDA 
(Food and Drug Administration) has asked for additional patient safety monitoring.  The 
long pipeline development time, the lack of financial support and the critical concern about 
safety issues, place these probes far away from the clinical setting. 
In conclusion, the need for noninvasive biomarkers in liver fibrosis, inflammation and 
steatosis to detect, stage and follow-up chronic liver disease is clear. Additional areas of 
research are nonetheless still lacking such as head-to-head comparisons of several 
noninvasive methods, defining cut-offs values for specific diseases, standardisation and 
repeatability and reproducibility assessments. Moreover, longitudinal studies to look at 
disease progression, regression under treatment and final outcomes are needed. 
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Truthfully, I think that the ideal biomarker will probably be a composite biomarker. The road 
ahead seems long, very long… as the “… man in the dark room, looking for the black cat…” that 
could be hiding!     
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